Kraig Biocraft Laboratories (KBLB) 10-K 29 Mar 23 2022 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2022	Mar. 29, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	000-56232
Entity Registrant Name	KRAIG BIOCRAFT LABORATORIES, INC.
Entity Central Index Key	0001413119
Entity Tax Identification Number	83-0459707
Entity Incorporation, State or Country Code	WY
Entity Address, Address Line One	2723 South State St. Suite 150
Entity Address, City or Town	Ann Arbor
Entity Address, State or Province	MI
Entity Address, Postal Zip Code	48104
City Area Code	734
Local Phone Number	619-8066
Title of 12(g) Security	Class A Common Stock, no par value
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 49,980,154
Entity Common Stock, Shares Outstanding		1,033,374,219
ICFR Auditor Attestation Flag	false
Auditor Firm ID	2738
Auditor Name	M&K CPAS, PLLC
Auditor Location	Houston, TX

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current Assets
Cash	$ 3,862,716	$ 2,355,060
Inventory	6,580
Prepaid expenses	15,665	11,055
Deposit	98,480
Total Current Assets	3,983,441	2,366,115
Property and Equipment, net	87,861	110,943
Investment in gold bullions (cost $450,216 and $450,216, respectively)	437,251	437,212
Operating lease right-of-use asset, net	58,849	104,124
Security deposit	3,518	3,518
Total Assets	4,570,920	3,021,912
Current Liabilities
Accounts payable and accrued expenses	540,339	587,794
Accounts payable and accrued expenses - related party	5,715,008	5,244,560
Note payable - related party	1,617,000	1,657,000
Loan payable	95,244	60,000
Royalty agreement payable - related party	65,292	65,292
Operating lease liability, current	39,200	44,577
Convertible note payable, net of debt discount of $0 and $246,577, respectively		503,423
Total Current Liabilities	8,072,083	8,162,646
Long Term Liabilities
Loan payable, net of current		95,244
Operating lease liability, net of current	20,697	59,897
Total Liabilities	8,092,780	8,317,787
Commitments and Contingencies (Note 9)
Stockholders’ Deficit
Preferred stock value
Common Stock Issuable, 1,122,311 and 1,122,311 shares, respectively	22,000	22,000
Additional paid-in capital	10,834,729	9,894,179
Accumulated Deficit	(46,657,000)	(42,814,986)
Total Stockholders’ Deficit	(3,521,860)	(5,295,875)
Total Liabilities and Stockholders’ Deficit	4,570,920	3,021,912
Series A Preferred Stock [Member]
Stockholders’ Deficit
Preferred stock value	5,217,800	5,217,800
Common Class A [Member]
Stockholders’ Deficit
Common stock value	27,060,611	22,385,132
Common Class B [Member]
Stockholders’ Deficit
Common stock value

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Investment owned, at cost	$ 450,216	$ 450,216
Debt discount, net	$ 0	$ 246,577
Preferred stock, no par value	$ 0	$ 0
Preferred stock, shares authorized	Unlimited	Unlimited
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock issuable	1,122,311	1,122,311
Series A Preferred Stock [Member]
Preferred stock, no par value	$ 0	$ 0
Preferred stock, shares issued	2	2
Preferred stock, shares outstanding	2	2
Common Class A [Member]
Common stock, no par value	$ 0	$ 0
Common stock, shares authorized	Unlimited	Unlimited
Common stock, shares issued	1,030,940,008	927,378,166
Common stock, shares outstanding	1,030,940,008	927,378,166
Common Class B [Member]
Common stock, no par value	$ 0	$ 0
Common stock, shares authorized	Unlimited	Unlimited
Common stock, shares issued	0	0
Common stock, shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue
Operating Expenses
General and Administrative	825,460	1,496,725
Professional Fees	339,710	326,982
Officer’s Salary	779,742	734,427
Rent - Related Party		3,683
Research and Development	176,431	197,745
Total Operating Expenses	2,121,343	2,759,562
Loss from Operations	(2,121,343)	(2,759,562)
Other Income/(Expenses)
Gain on debt extinguishment (PPP)		90,100
Net change in unrealized depreciation on investment in gold bullion	38	(13,004)
Interest expense	(609,129)	(660,419)
Amortization of debt issue costs	(1,111,580)	(4,702,918)
Total Other Income/(Expenses)	(1,720,671)	(5,286,241)
Net (Loss) before Provision for Income Taxes	(3,842,014)	(8,045,803)
Provision for Income Taxes
Net (Loss)	$ (3,842,014)	$ (8,045,803)
Net Income (Loss) Per Share - Basic and Diluted	$ 0	$ (0.01)
Weighted average number of shares outstanding during the period - Basic and Diluted	974,307,366	877,612,187

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash Flows From Operating Activities:
Net Loss	$ (3,842,014)	$ (8,045,803)
Adjustments to reconcile net loss to net cash used in operations
Depreciation expense	28,103	26,137
Gain on debt extinguishment (PPP)		(90,100)
Net change in unrealized appreciation and depreciation in gold bullions	(38)	13,004
Stock issued for services		242,100
Loss on disposal of fixed assets		49,321
Amortization of debt discount	1,111,580	4,702,918
Imputed interest - related party	80,849	82,851
Warrants issued/(cancelled) to consultants	234,698	600,278
Changes in operating assets and liabilities:
(Increase) in inventory	(6,580)
(Increase) in prepaid expenses	(4,610)	(8,467)
(Increase) in deposits	(98,480)
Operating lease right-of-use, net	45,275	90,072
Increase in accrued expenses and other payables - related party	470,448	441,574
Increase in accounts payable	138,159	199,723
Operating lease liabilities, current	(44,577)	(104,417)
Net Cash Used In Operating Activities	(1,887,187)	(1,800,809)
Cash Flows From Investing Activities:
Investment in gold bullions		(450,216)
Purchase of Fixed Assets	(5,021)	(97,154)
Net Cash Used In Investing Activities	(5,021)	(547,370)
Cash Flows From Financing Activities:
Repayment of notes payable - related party	(40,000)
Proceeds from convertible note payable, net of original issue discount	2,760,000	3,670,000
Principal payments on debt	(60,000)	(50,000)
Proceeds from warrant exercise	739,864	266,332
Net Cash Provided by Financing Activities	3,399,864	3,886,332
Net Increase in Cash	1,507,656	1,538,153
Cash at Beginning of Year	2,355,060	816,907
Cash at End of Year	3,862,716	2,355,060
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid for taxes
Supplemental disclosure of non-cash investing and financing activities:
Shares issued in connection with cashless warrants exercise		292,533
Warrant discount in connection with convertible debt	625,003	3,670,000
Adoption of lease standard ASC 842		115,390
Cancellation and forgiveness of lease - related party		44,419
Cancellation and forgiveness of lease		241,800
Shares issued in connection with convertible note payable	$ 3,935,615	$ 4,461,931

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders' Deficit - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Common Stock [Member] Common Class A [Member]	Common Stock [Member] Common Class B [Member]	Common Stock to be Issued [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 5,217,800	$ 17,122,236		$ 22,000	$ 5,833,583	$ (34,769,183)	$ (6,573,564)
Beginning balance, shares at Dec. 31, 2020	2	854,410,001		1,122,311
Warrants issued for services - related parties					556,276		556,276
Warrants issued for services					86,709		86,709
Common stock issued for services		$ 242,100					242,100
Common stock issued for services, shares		3,000,000
Cancellations of warrants					(42,707)		(42,707)
Exercise of warrants in exchange for stock		$ 558,865			(292,533)		266,332
Exercise of warrants in exchange for stock, shares		5,296,250
Convertible debt conversion into common stock ($0.0744 - $0.1540/Sh)		$ 4,461,931					4,461,931
Convertible debt conversion into common stock ($0.0744 - $0.1540/Sh), shares		64,671,915
Contributed capital - related party
Imputed interest - related party					82,851		82,851
Warrant discount					3,670,000		3,670,000
Net loss						(8,045,803)	(8,045,803)
Ending balance, value at Dec. 31, 2021	$ 5,217,800	$ 22,385,132		22,000	9,894,179	(42,814,986)	(5,295,875)
Ending balance, shares at Dec. 31, 2021	2	927,378,166
Warrants issued for services - related parties					202,895		202,895
Warrants issued for services					31,803		31,803
Imputed interest - related party					80,849		80,849
Warrant discount					625,003		625,003
Net loss						(3,842,014)	(3,842,014)
Exercise of warrants in exchange for cash ($0.06/Sh and $0.08/Sh)		$ 739,864					739,864
Exercise of warrants in exchange for cash ($0.06/Sh and $0.08/Sh), shares		11,097,959
Convertible debt and accrued interest conversion into common stock ($0.0253/Sh-$0.06430/Sh)		$ 3,935,615					3,935,615
Convertible debt and accrued interest conversion into common stock ($0.0253/Sh-$0.06430/Sh), shares		92,463,883
Ending balance, value at Dec. 31, 2022	$ 5,217,800	$ 27,060,611		$ 22,000	$ 10,834,729	$ (46,657,000)	$ (3,521,860)
Ending balance, shares at Dec. 31, 2022	2	1,030,940,008

Consolidated Statement of Cha_2

Consolidated Statement of Changes in Stockholders' Deficit (Parenthetical) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2022
Debt conversion price, increase	$ 0.0744
Debt conversion price, decrease	$ 0.1540
Minimum [Member]
Warrant exercise price		$ 0.06
Debt conversion price		0.0253
Maximum [Member]
Warrant exercise price		0.08
Debt conversion price		$ 0.06430

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION Organization On July 15, 2022, the Company signed an agreement with Global Silk Solutions Joint Stock Company (GSS). Under this agreement, GSS will serve as a contract manufacturer for the Company’s recombinant spider silk. Kraig Biocraft Laboratories, Inc. (the “Company”) was incorporated under the laws of the State of Wyoming on April 25, 2006. The Company was organized to develop high strength, protein based fiber, using recombinant DNA technology, for commercial applications in the textile and specialty fiber industries. Kraig Biocraft Laboratories, Inc. (the “Company”) was incorporated under the laws of the State of Wyoming on April 25, 2006. The Company was organized to develop high strength, protein based fiber, using recombinant DNA technology, for commercial applications in the textile and specialty fiber industries. On March 5, 2018, the Company issued a board resolution authorizing investment in a Vietnamese subsidiary and appointing a representative for the subsidiary. On April 24, 2018, the Company announced that it had received its investment registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd. On May 1, 2018, the Company announced that it had received its enterprise registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd Foreign Currency The assets and liabilities of Prodigy Textiles, Co., Ltd. (the Company’s Vietnamese subsidiary) whose functional currency is the Vietnamese Dong, are translated into US dollars at period-end exchange rates prior to consolidation. Income and expense items are translated at the average rates of exchange prevailing during the period. The adjustments resulting from translating the Company’s financial statements are reflected as a component of other comprehensive (loss) income. Foreign currency transaction gains and losses are recognized in net earnings based on differences between foreign exchange rates on the transaction date and settlement date. Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Cash The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. There were no Loss Per Share Basic and diluted net loss per common share is computed based upon the weighted average common shares outstanding as defined by the Financial Accounting Standards Board (“FASB” Accounting Standards Codification (“ASC”) No. 260, “Earnings per Share.” For December 31, 2022 and December 31, 2021, warrants were not included in the computation of income/ (loss) per share because their inclusion is anti-dilutive. The computation of basic and diluted loss per share for December 31, 2022 and 2021 excludes the common stock equivalents of the following potentially dilutive securities because their inclusion would be anti-dilutive: SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE December 31, 2022 December 31, 2021 Stock Warrants (Exercise price - $ 0.001 0.25 54,660,032 48,972,277 Stock Options (Exercise price - $ 0.1150 26,520,000 26,802,500 Convertible Debt - 6,470,674 Convertible Preferred Stock 2 2 Total 81,180,034 82,245,453 Research and Development Costs The Company expenses all research and development costs as incurred for which there is no alternative future use. These costs also include the expensing of employee compensation and employee stock based compensation. For the the years ended December 31, 2022 and 2021, the Company had $ 176,431 197,745 Advertising Expense The Company follows the policy of charging the costs of advertising to expense as incurred. There was no advertising expense in the years ended December 31, 2022 and 2021. Income Taxes The Company accounts for income taxes under FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC No. 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC No. 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2022 2021 Expected income tax (recovery) expense at the statutory rate of 21 $ (806,823 ) $ (1,689,619 ) Tax effect of expenses that are not deductible for income tax purposes (net of other amounts deductible for tax purposes) 282,808 1,141,619 Change in valuation allowance 524,014 548,000 Provision for income taxes $ - $ - The components of deferred income taxes are as follows: SCHEDULE OF COMPONENTS DEFERRED INCOME TAXES 2022 2021 Years Ended December, 2022 2021 Deferred tax liability: $ - $ - Deferred tax asset Net Operating Loss Carryforward 4,887,351 4,363,336 Valuation allowance (4,887,351 ) (4,343,336 ) Net deferred tax asset - - Net deferred tax liability $ - $ - The valuation allowance was established to reduce the deferred tax asset to the amount that will more likely than not be realized. This is necessary due to the Company’s continued operating losses and the uncertainty of the Company’s ability to utilize all of the net operating loss carryforwards before they will expire through the year 2041. The net change in the valuation allowance for the year ended December 31, 2022 and 2021 was an increase of $ 524,014 548,000 Stock-Based Compensation The Company accounts for stock-based compensation for employees and directors in accordance with ASC 718, Compensation (“ASC 718”). ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Under the provisions of ASC 718, stock-based compensation costs are measured at the grant date, based on the fair value of the award, and are recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718 and, excess tax benefits realized from the exercise of stock-based awards are classified as cash flows from operating activities. All excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) are recognized as income tax expense or benefit in the condensed consolidated statements of operations. The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in ASU 2018-07. Recent Accounting Pronouncements Changes to accounting principles are established by the FASB in the form of ASU’s to the FASB’s Codification. We consider the applicability and impact of all ASU’s on our financial position, results of operations, stockholders’ deficit, cash flows, or presentation thereof. Management has evaluated all recent accounting pronouncements as issued by the FASB in the form of Accounting Standards Updates (“ASU”) through the date these financial statements were available to be issued and found no recent accounting pronouncements issued, but not yet effective accounting pronouncements, when adopted, will have a material impact on the financial statements of the Company. In September 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, Measurement of Credit Losses on Financial Instruments, which supersedes current guidance by requiring recognition of credit losses when it is probable that a loss has been incurred. The new standard requires the establishment of an allowance for estimated credit losses on financial assets including trade and other receivables at each reporting date. The new standard will result in earlier recognition of allowances for losses on trade and other receivables and other contractual rights to receive cash. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842), which extends the effective date of Topic 326 for certain companies until fiscal years beginning after December 15, 2022. The new standard will be effective for the Company in the first quarter of fiscal year beginning January 1, 2023, and early adoption is permitted. We adopted this pronouncement on January 1, 2021; however, the adoption of this standard did not have a material effect on the Company’s financial statements. In December 2019, the FASB issued ASU 2019-12, “Simplifying the Accounting for Income Taxes.” This guidance, among other provisions, eliminates certain exceptions to existing guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. This guidance also requires an entity to reflect the effect of an enacted change in tax laws or rates in its effective income tax rate in the first interim period that includes the enactment date of the new legislation, aligning the timing of recognition of the effects from enacted tax law changes on the effective income tax rate with the effects on deferred income tax assets and liabilities. Under existing guidance, an entity recognizes the effects of the enacted tax law change on the effective income tax rate in the period that includes the effective date of the tax law. ASU 2019-12 is effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted. We adopted this pronouncement on January 1, 2021; however, the adoption of this standard did not have a material effect on the Company’s financial statements. However, based on the Company’s history of immaterial credit losses from trade receivables, management does not expect that the adoption of this standard will have a material effect on the Company’s financial statements. In August 2020, FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity; Own Equity (“ASU 2020-06”), as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes from GAAP separation models for convertible debt that require the convertible debt to be separated into a debt and equity component, unless the conversion feature is required to be bifurcated and accounted for as a derivative or the debt is issued at a substantial premium. As a result, after adopting the guidance, entities will no longer separately present such embedded conversion features in equity and will instead account for the convertible debt wholly as debt. The new guidance also requires use of the “if-converted” method when calculating the dilutive impact of convertible debt on earnings per share, which is consistent with the Company’s current accounting treatment under the current guidance. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, but only at the beginning of the fiscal year. The Company adopted the guidance under ASU 2020-06 on January 1, 2022. The adoption of this guidance and had no material impact on the Company’s financial statements. Equipment The Company values property and equipment at cost and depreciates these assets using the straight-line method over their expected useful life. In accordance with FASB ASC No. 360, Property, Plant and Equipment, There were no Fair Value of Financial Instruments We hold certain financial assets, which are required to be measured at fair value on a recurring basis in accordance with the Statement of Financial Accounting Standard No. 157, “Fair Value Measurements” The three levels of the fair value hierarchy under ASC Topic 820-10 are described below: ● Level 1 - Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. We believe our carrying value of level 1 instruments approximate their fair value at December 31, 2022 and 2021. ● Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. ● Level 3 - Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. We consider depleting assets, asset retirement obligations and net profit interest liability to be Level 3. We determine the fair value of Level 3 assets and liabilities utilizing various inputs, including NYMEX price quotations and contract terms. SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS December 31, 2022 December 31, 2021 Level 1 – Investment in Gold $ 437,251 $ 437,212 Level 2 $ - $ - Level 3 $ - $ - Total $ 437,251 $ 437,212 The Board of Directors, who serves as the Custodian, is responsible for the safekeeping of gold bullion owned by the Company. Fair value of the gold bullion held by the Company is based on that day’s London Bullion Market Association (“LBMA”) Gold Price PM. “LBMA Gold Price PM” is the price per fine troy ounce of gold, stated in U.S. dollars, determined by ICE Benchmark Administration (“IBA”) following an electronic auction consisting of one or more 30-second rounds starting at 3:00 p.m. (London time), on each day that the London gold market is open for business and published shortly thereafter. The following tables summarize activity in gold bullion for the quarter ended December 31, 2022: SCHEDULE OF GOLD IN BULLION Year Ended December 31, 2022 Ounces Cost Fair Value Beginning balance - $ - $ - Investment in Gold bullion 239 1,884 450,216 Net change in unrealized loss - - (13,004 ) Balance December 31, 2021 239 $ 1,884 $ 437,212 Net change in unrealized gain - 38 38 Balance December 31, 2022 239 $ 1,829 $ 437,251 Revenue Recognition Effective January 1, 2018, the Company adopted ASC No. 606 — Revenue from Contracts with Customers. Under ASC No. 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the years ended December 31, 2022 and 2021, the Company recognized $ 0 0 Concentration of Credit Risk The Company at times has cash in banks in excess of FDIC insurance limits. At December 31, 2022 and December 31, 2021, the Company had approximately $ 3,285,197 2,092,420 Original Issue Discount For certain notes issued, the Company provides the debt holder with an original issue discount. The original issue discount is recorded as a debt discount, reducing the face amount of the note, and is amortized to amortization of original issue discount in the consolidated statements of operations over the life of the debt. Debt Issue Cost Debt issuance cost paid to lenders, or third parties are recorded as debt discounts and amortized to interest expense in the consolidated statements of operations, over the life of the underlying debt instrument. Deposit During the year ended December 31, 2022, the Company paid $ 98,480

GOING CONCERN

GOING CONCERN	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 2 GOING CONCERN As reflected in the accompanying financial statements, the Company has a working capital deficiency of $ 4,088,642 3,521,860 1,887,187 Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern.

EQUIPMENT

EQUIPMENT	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
EQUIPMENT	NOTE 3 EQUIPMENT At December 31, 2022 and December 31, 2021, property and equipment, net, is as follows: SCHEDULE OF PROPERTY AND EQUIPMENT December 31, 2022 December 31, 2021 Estimated Useful Lives (Years) Automobile $ 41,805 $ 41,805 5 Laboratory Equipment 123,911 118,890 5 10 Office Equipment 7,260 7,260 5 10 Leasehold Improvements 82,739 82,739 2 5 Less: Accumulated Depreciation (167,854 ) (139,751 ) Total Property and Equipment, net $ 87,861 $ 110,943 Depreciation expense for the years ended December 31, 2022 and 2021, was $ 28,103 26,137

RIGHT TO USE ASSETS AND LEASE L

RIGHT TO USE ASSETS AND LEASE LIABILITITY	12 Months Ended
	Dec. 31, 2022
Right To Use Assets And Lease Liabilitity
RIGHT TO USE ASSETS AND LEASE LIABILITITY	NOTE 4 - RIGHT TO USE ASSETS AND LEASE LIABILITITY We determine if an arrangement is a lease, or contains a lease, at inception and record the leases in our financial statements upon lease commencement, which is the date when the underlying asset is made available for use by the lessor. We have a lease agreement with lease and non-lease components and have elected to utilize the practical expedient to account for lease and non-lease components together as a single combined lease component, from both a lessee and lessor perspective with the exception of direct sales-type leases and production equipment classes embedded in supply agreements. From a lessor perspective, the timing and pattern of transfer are the same for the non-lease components and associated lease component and, the lease component, if accounted for separately, would be classified as an operating lease. We have elected not to present short-term leases on the balance sheet as these leases have a lease term of 12 months or less at lease inception and do not contain purchase options or renewal terms that we are reasonably certain to exercise. All other lease assets and lease liabilities are recognized based on the present value of lease payments over the lease term at commencement date. Because our lease does not provide an implicit rate of return, we used our incremental borrowing rate based on the information available at lease commencement date in determining the present value of lease payments. In general, leases, where we are the lessee, may include options to extend the lease term f. These leases may include options to terminate the lease prior to the end of the agreed upon lease term. For purposes of calculating lease liabilities, lease terms include options to extend or terminate the lease when it is reasonably certain that we will exercise such options. Lease expense for operating leases is recognized on a straight-line basis over the lease term as cost of revenues or operating expenses depending on the nature of the leased asset. Certain operating leases provide for annual increases to lease payments based on an index or rate. We calculate the present value of future lease payments based on the index or rate at the lease commencement date. Differences between the calculated lease payment and actual payment are expensed as incurred. Amortization of finance lease assets is recognized over the lease term as cost of revenues or operating expenses depending on the nature of the leased asset. Interest expense on finance lease liabilities is recognized over the lease term in interest expense. Since September of 2015, we rent office space at 2723 South State Street, Suite 150, Ann Arbor, Michigan 48104, which is our principal place of business. We pay an annual rent of $ 2,508 On January 23, 2017 the Company signed an 8 960 0 3,683 44,419 On September 5, 2019, we signed a two 5,000 42,000 44,800 42,000 44,800 79,862 79,862 On May 9, 2019 the Company signed a 5 4,560.57 45,150 5 241,800 On July 1, 2021, the Company signed a 5 6,000 8,645 The tables below present information regarding the Company’s operating lease assets and liabilities at December 31, 2022; At December 31, 2022 and 2021, the Company had no financing leases as defined in ASC 842, “Leases.” SCHEDULE OF OPERATING LEASES December 31, 2022 December 31, 2021 Assets Operating lease - right-of-use asset - non-current $ 58,849 $ 104,124 Liabilities Operating lease liability $ 59,897 $ 104,124 Weighted-average remaining lease term (years) 2.08 2.69 Weighted-average discount rate 8 % 8 % The components of lease expense were as follows: Operating lease costs Amortization of right-of-use operating lease asset $ 52,043 $ 96,978 Total operating lease costs $ 52,043 $ 96,978 Supplemental cash flow information related to operating leases was as follows: Operating cash outflows from operating lease (obligation payment) $ 51,344 $ 130,147 Right-of-use asset obtained in exchange for new operating lease liability $ - $ 115,389 Future minimum lease payments required under leases that have initial or remaining non-cancelable lease terms in excess of one year at December 31, 2022: SCHEDULE OF MINIMUM LEASE PAYMENTS 2023 $ 42,242 2024 8,644 2025 8,644 2026 5,763 Total lease payments 65,294 Less: amount representing interest (5,397 ) Total lease obligations 59,897 Less: current portion of operating lease liability (39,200 ) Long-term portion operating lease liability $ 20,697

NOTE PAYABLE _ RELATED PARTY

NOTE PAYABLE – RELATED PARTY	12 Months Ended
	Dec. 31, 2022
Note Payable Related Party
NOTE PAYABLE – RELATED PARTY	NOTE 5 NOTE PAYABLE – RELATED PARTY On June 6, 2016, the Company received a $ 50,000 30,000 100,000 15,000 20,000 15,000 15,000 20,000 26,000 11,000 20,000 3,000 30,000 30,000 20,000 20,000 17,000 100,000 100,000 100,000 100,000 100,000 100,000 150,000 100,000 100,000 100,000 30,000 30,000 35,000 70,000 3 On January 26, 2022, the Company repaid $ 40,000 Total loan payable to principal stockholder for as of December 31, 2022 is $ 1,617,000 Total loan payable to this principal stockholder as of December 31, 2021 is $ 1,657,000 During the year ended December 31, 2022, the Company recorded $ 80,849 54,755 During the year ended December 31, 2021, the Company recorded $ 82,851 53,671

LOAN PAYABLE

LOAN PAYABLE	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
LOAN PAYABLE	NOTE 6 LOAN PAYABLE On March 1, 2019, the Company entered into an unsecured promissory note with Notre Dame - an unrelated party in the amount of $ 265,244 in exchange for outstanding account payable due to the debtor. Pursuant to the terms of the note, the note bears 10 % interest per year from the date of default until the date the loan is paid in full. The term of the loan is twenty-four months . The loan repayment commenced immediately over a twenty-four month period according to the following table. During the year ended December 31, 2022, the Company paid $ 60,000 of the loan balance. The remaining loan balance as of December 31, 2022 is $ 95,244 1. $ 1,000 2. $ 2,000 3. $ 5,000 4. Final payment of all remaining balance, in the amount of $ 180,224 On July 8, 2021, the Company entered into an amendment to the March 1, 2019 agreement. As of the date of the amendment, the remaining outstanding balance is $ 180,244 1. $ 5,000 2. Final payment of the remaining balance in the amount of $ 115,244 57,622 57,622

CONVERTIBLE NOTES

CONVERTIBLE NOTES	12 Months Ended
	Dec. 31, 2022
Convertible Notes
CONVERTIBLE NOTES	NOTE 7 CONVERTIBLE NOTES The Company issued a $ 1,000,000 thirteen 10 5 50,000 950,000 The note contains a discount to market feature, whereby, the lender can purchase stock at 90% of the lowest trading price for a period of ten (10) days preceding the conversion date Additionally, the Company issued 3,125,000 5 2,599,066 SCHEDULE OF FAIR VALUE WARRANTS Stock Price $ 0.14 Exercise price $ 0.16 Expected term (in years) 5 Expected volatility 60.64 % Annual rate of quarterly dividends 0 % Risk free interest rate 0.10 % The Company has determined that ASC 815 does not apply since the Company has unlimited authorized shares, which in turn satisfies the requirement of having sufficient authorized shares available to settle any potential instruments that may require physical net-share settlement. Pursuant to ASC 470, the Company will record a beneficial conversion feature (“BCF”) based upon the relative fair value of the conversion feature within the convertible note and the related warrants. The BCF cannot exceed the face amount of the note, therefore, the discount for this note is $ 1,000,000 The Company also paid $ 86,000 On March 25, 2021, the Company entered into one year 4,000,000 500,000 March 25, 2022 10 The note contains a discount to market feature, whereby, the lender can purchase stock at 80% of the lowest trading price for a period of ten (10) days preceding the conversion date 500,000 3,000,000 Additionally, the Company issued 8,000,000 5 3,359,716 Stock Price $ 0.15 Exercise price $ 0.25 Expected term (in years) 5 Expected volatility 100.76 % Annual rate of quarterly dividends 0 % Risk free interest rate 0.07 % The Company has determined that ASC 815 does not apply since the Company has unlimited authorized shares, which in turn satisfies the requirement of having sufficient authorized shares available to settle any potential instruments that may require physical net-share settlement. Pursuant to ASC 470, the Company will record a beneficial conversion feature (“BCF”) based upon the relative fair value of the conversion feature within the convertible note and the related warrants. The BCF cannot exceed the face amount of the note, therefore, the discount for this note is $ 3,670,000 The Company also paid $ 330,000 On January 21, 2022, the Company issued 3,935,417 250,000 2,260 On January 31, 2022, the Company issued 4,569,059 250,000 42,877 On February 16, 2022, the Company issued 3,924,443 250,000 1,164 The Company issued a $ 1,500,000 thirteen February 18, 2023 10 10,000 1,490,000 The note contains a discount to market feature, whereby, the lender can purchase stock at 85% of the lowest trading price for a period of ten (10) days preceding the conversion date Additionally, the Company issued 12,000,000 5 0.12 4,285,714 0.14 1,071,437 Stock Price $ 0.08 Exercise price $ 0.12 Exercise price $ 0.14 Expected term (in years) 5 Expected volatility 124.10 % Annual rate of quarterly dividends 0 % Risk free interest rate 0.58 % The Company has determined that ASC 815 does not apply since the Company has unlimited authorized shares, which in turn satisfies the requirement of having sufficient authorized shares available to settle any potential instruments that may require physical net-share settlement. In connection with $ 1,500,000 16,785,714 625,003 The Company also paid $ 115,000 As of December 31, 2022, the above three notes were fully converted, with the no remaining balance due. On April 14, 2022, the Company issued 2,358,380 150,000 1,644 On April 29, 2022, the Company issued 4,272,417 250,000 5,918 On May 17, 2022, the Company issued 3,628,325 200,000 5,726 On June 6, 2022, the Company issued 3,549,793 200,000 5,178 On June 14, 2022, the Company issued 2,902,922 100,000 60,822 On June 21, 2022, the Company issued 3,393,979 150,000 3,068 On June 30, 2022, the Company issued 3,401,877 150,000 3,425 On July 19, 2022, the Company issued 4,364,987 200,000 6,027 On August 18, 2022, the Company issued 4,325,913 200,000 7,644 On September 8, 2022, the Company issued 3,396,898 150,000 4,219 On September 26, 2022, the Company issued 3,605,259 150,000 2,863 On October 11, 2022, the Company issued 2,907,240 100,000 1,753 On October 18, 2022, the Company issued 4,782,778 150,000 658 On October 26, 2022, the Company issued 5,487,951 150,000 370 On October 31, 2022, the Company issued 6,510,348 150,000 28,384 On November 1, 2022, the Company issued 9,236,212 250,000 301 On November 14, 2022, the Company issued 5,974,335 150,000 1,151 On November 17, 2022, the Company issued 5,935,350 150,000 164 The Company issued a $ 1,500,000 thirteen May 11, 2023 10 The note contains a discount to market feature, whereby, the lender can purchase stock at 85% of the lowest trading price for a period of ten (10) days preceding the conversion date The Company also paid $ 115,000 The following represents a summary of the Company’s convertible debt at December 31, 2022: SUMMARY OF CONVERTIBLE DEBT Convertible Note Payable Amounts In-Default Balance – December 31, 2020 $ 50,505 - Proceeds 4,000,000 Debt discount recorded (4,000,000 ) Conversion of debt into common shares (4,250,000 ) Amortization of debt discount 4,702,918 Balance – December 31, 2021 $ 503,423 $ - Proceeds 3,000,000 - Debt discount and issue costs recorded (865,000 )              - Conversion of debt into common shares (3,750,003 ) Amortization of debt discount 1,111,580 - Balance – December 31, 2022 $ - $ - Accrued Interest Payable Amounts In-Default Balance – December 31, 2020 $ 5,479 - Interest Expense 2021 238,110 Interest conversion into common shares (211,932 ) Balance – December 31, 2021 31,657 $ - Interest Expense December 31, 2022 153,955               - Interest conversion into common shares (185,612 ) Balance – December 31, 2022 $ - $ -

STOCKHOLDERS_ DEFICIT

STOCKHOLDERS’ DEFICIT	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
STOCKHOLDERS’ DEFICIT	NOTE 8 STOCKHOLDERS’ DEFICIT (A) Common Stock Issued for Cash On March 9, 2019, the Company entered into a purchase agreement with one investor (the “Purchase Agreement”). Pursuant to the Purchase Agreement, the Company issued the investor 14,797,278 0.06758 1,000,000 14,797,278 14,797,278 0.06 7,398,639 0.08 ● ½ of all $ 0.06 March 8, 2021 ● ½ of all $ 0.06 March 8, 2022 ● ½ of all $ 0.08 March 8, 2022 ● ½ of all $ 0.08 March 8, 2023 On March 2, 2021, the Company determined to amend and extend the expiration of the warrants expiring on March 8, 2021 as follows: ● 1,479,728 0.06 March 8, 2021 ● 1,479,728 0.06 May 8, 2021 ● 1,479,728 0.06 July 8, 2021 December 8, 2021 ● 1,479,728 0.06 September 8, 2021 ● 1,479,727 0.06 November 8, 2021 On March 2, 2021, the Company issued 1,479,728 1,479,728 88,784 On May 4, 2021, the Company issued 1,479,728 1,479,728 88,784 On December 6, 2021, the Company issued 1,479,728 1,479,728 88,784 On February 15, 2022, the Company issued 7,398,639 shares of Common stock in connection with the exercise of 7,398,639 warrants for $ 443,918 On February 15, 2022, the Company issued 3,699,320 shares of Common stock in connection with the exercise of 3,699,320 warrants for $ 295,946 (B) Common Stock Issued for Services Shares issued for services as mentioned below were valued at the closing price of the stock on the date of grant. On September 3, 2021, the Company issued 3,000,000 242,100 0.0807 (C) Common Stock Warrants and Options On March 5, 2021, the Company issued 786,280 2,000,000 On March 2, 2021, the Company issued 1,479,728 1,479,728 88,784 On May 4, 2021, the Company issued 1,479,728 1,479,728 88,784 On December 6, 2021, the Company issued 1,479,728 1,479,728 88,784 On February 15, 2022, the Company issued 7,398,639 shares of Common stock in connection with the exercise of 7,398,639 warrants for $ 443,918 . On February 15, 2022, the Company issued 3,699,320 shares of Common stock in connection with the exercise of 3,699,320 warrants for $ 295,946 On April 11, 2022, the Company extended the expiration date of the warrant issued on May 28, 2015 to May 27, 2025. No additional expense was recorded due to rate difference being de minimis. On January 25, 2021, the Company issued a 7-year option to purchase 2,500,000 0.134 310,165 Options vest 33.3% on the year one anniversary of the grant date, 33.3% will vest on the second anniversary, and 33.3% will vest on the third year anniversary as long as the employee remains with the Company at the end of each successive year for three years. Options will be exercisable on January 25, 2021, and for a period of 7 years expiring on January 25, 2028 98,625 SCHEDULE OF OPTION ASSUMPTION Expected dividends 0 % Expected volatility 133.22 % Expected term 7 Risk free interest rate 1.46 % Expected forfeitures 0 % On February 19, 2020 the Company issued a 10-year option to purchase 6,000,000 0.115 626,047 Black-Scholes option-pricing model on the date of grant and 2,000,000 options are fully vested on the date granted and 1,000,000 options vest at the end of each successive year for four years. Options will be exercisable on February 19, 2021, and for a period of 10 years expiring on February 19, 2030 104,270 Expected dividends 0 % Expected volatility 125.19 % Expected term 3 Risk free interest rate 1.50 % Expected forfeitures 0 % On February 19, 2020 the Company issued a 7-year option to purchase 1,340,000 0.115 133,063 Black-Scholes option-pricing model on the date of grant and 268,000 options are fully vested on the date granted and the remaining option vest equally over the remaining 4 years at the end of each successive year. Options will be exercisable on February 19, 2021, and for a period of 6 years expiring on February 19, 2027 31,803 Expected dividends 0 % Expected volatility 125.19 % Expected term 6 Risk free interest rate 1.46 % Expected forfeitures 0 % Warrant activity for the years ended December 31, 2022 and 2021 are summarized as follows: SCHEDULE OF WARRANTS ACTIVITY Weighted Average Weighted Remaining Aggregate Warrants Number of Warrants Average Exercise Price Contractual Term (Years) Intrinsic Value Outstanding - December 31, 2020 49,120,917 $ 0.14 1.83 $ 3,013,010 Exercisable - December 31, 2020 49,120,917 $ 0.14 1.83 $ 3,013,010 Granted 8,500,000 $ 0.24 4.19 - Exercised (5,439,184 ) $ 0.06 4 - Cancelled/Forfeited (4,209,456 ) $ 0.07 - - Outstanding - December 31, 2021 48,972,279 $ 0.12 2.64 $ 1,248,452 Exercisable - December 31, 2021 48,972,279 $ 0.12 2.64 $ 1,248,452 Granted 16,785,714 $ 0.12 4.05 - Exercised (11,097,959 ) $ 0.07 - - Cancelled/Forfeited - $ - - - Outstanding - December 31, 2022 54,660,034 $ 0.13 3.04 $ 319,000 Exercisable - December 31, 2022 54,660,034 $ 0.13 3.04 $ 319,000 For the year ended December 31, 2022, the following warrants were outstanding: SCHEDULE OF WARRANTS OUTSTANDING Exercise Price Warrants Weighted Average Aggregate $ 0.001 11,000,000 3.43 $ 321,000 $ 0.04 2,300,000 3.75 $ - $ 0.08 3,699,320 0.18 $ - $ 0.2299 8,250,000 2.21 $ - $ 0.16 3,125,000 2.95 $ - $ 0.25 8,000,000 3.23 $ - $ 0.1160 500,000 2.52 $ - $ 0.12 12,500,000 4.05 $ - $ 0.14 4,285,714 4.05 $ - For the year ended December 31, 2021, the following warrants were outstanding: Exercise Price Warrants Weighted Average Aggregate $ 0.001 11,000,000 3.07 $ 913,900 $ 0.056 1,000,000 3.52 $ 27,900 $ 0.04 2,300,000 4.75 $ 100,970 $ 0.06 7,398,639 0.18 $ 176,827 $ 0.08 3,699,320 0.18 $ 14,427 $ 0.08 3,699,320 1.18 $ 14,427 $ 0.2299 8,250,000 3.21 $ - $ 0.16 3,125,000 4.95 $ - $ 0.25 8,000,000 4.23 $ - $ 0.1160 500,000 3.52 $ - Options activity for the years ended December 31, 2022 and 2021 are summarized as follows: SCHEDULE OF OPTIONS ACTIVITY Options Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding - December 31, 2020 27,340,000 $ 0.12 22.60 $ - Exercisable - December 31, 2020 27,340,000 $ 0.12 22.60 $ - Granted 2,500,000 $ 0.13 6.07 - Exercised (2,200,000 ) $ 0.12 9.00 - Cancelled/Forfeited (837,500 ) $ 0.12 6.00 - Outstanding - December 31, 2021 26,802,500 $ 0.12 19.12 $ - Exercisable - December 31, 2021 26,802,500 $ 0.12 19.12 $ - Granted - $ - - - Exercised - $ - - - Cancelled/Forfeited (282,500 ) $ 0.12 5.00 - Outstanding - December 31, 2022 26,520,000 $ 0.12 18.27 $ - Exercisable - December 31, 2022 26,520,000 $ 0.12 18.27 $ - For the year ended December 31, 2022, the following options were outstanding: SCHEDULE OF OPTIONS OUTSTANDING Weighted Average Exercise Options Options Remaining Price Outstanding Exercisable Contractual Life (in Years) $ 0.115 - 26,520,000 18.52 For the year ended December 31, 2021, the following options were outstanding: Weighted Average Exercise Options Options Remaining Price Outstanding Exercisable Contractual Life (in Years) $ 0.115 - 26,802,500 19.11 (D) Amendment to Articles of Incorporation On February 16, 2009, the Company amended its articles of incorporation to amend the number and class of shares the Company is authorized to issue as follows: ● Common stock Class A, unlimited no ● Common stock Class B, unlimited no ● Preferred stock, unlimited no Effective December 17, 2013, the Company amended its articles of incorporation to designate a Series A no (E) Common Stock Issued for Debt On October 11, 2022, the Company issued 2,907,240 100,000 1,753 On October 18, 2022, the Company issued 4,782,778 150,000 658 On October 26, 2022, the Company issued 5,487,951 150,000 370 On October 31, 2022, the Company issued 6,510,348 150,000 28,384 On November 1, 2022, the Company issued 9,236,212 250,000 301 On November 14, 2022, the Company issued 5,974,335 150,000 1,151 On November 17, 2022, the Company issued 5,935,350 150,000 164 As of November 17, 2022, the Company has satisfied all debentures to Yorkville Advisors. On September 26, 2022, the Company issued 3,605,259 150,000 2,863 On September 8, 2022, the Company issued 3,396,898 150,000 4,219 On August 18, 2022, the Company issued 4,325,913 200,000 7,644 On July 19, 2022, the Company issued 4,364,987 200,000 6,027 On June 30, 2022, the Company issued 3,401,877 150,000 3,425 On June 21, 2022, the Company issued 3,393,979 150,000 3,068 On June 14, 2022, the Company issued 2,902,922 100,000 60,822 On June 6, 2022, the Company issued 3,549,793 200,000 5,178 On May 17, 2022, the Company issued 3,628,325 200,000 5,726 On April 14, 2022, the Company issued 2,358,380 150,000 1,644 On April 29, 2022, the Company issued 4,272,417 250,000 5,918 On February 16, 2022, the Company issued 3,924,443 250,000 1,164 On January 21, 2022, the Company issued 3,935,417 250,000 2,260 On January 31, 2022, the Company issued 4,569,059 250,000 42,877 On April 23, 2021, the Company issued 836,574 100,000 1,644 On April 26, 2021, the Company issued 2,063,391 250,000 3,178 On April 30, 2021, the Company issued 2,058,686 250,000 3,630 338,654 On June 7, 2021, the Company issued 2,431,506 200,000 25,644 On June 23, 2021, the Company issued 2,422,195 200,000 10,247 On July 6, 2021, the Company issued 2,343,919 200,000 7,671 On July 20, 2021, the Company issued 1,664,823 100,000 60,822 On July 29, 2021, the Company issued 3,101,546 200,000 11,836 On August 16, 2021, the Company issued 2,277,273 150,000 6,904 On August 23, 2021, the Company issued 3,454,203 200,000 11,397 On August 30, 2021, the Company issued 2,284,808 150,000 3,082 On September 8, 2021, the Company issued 4,311,269 250,000 6,521 On September 14, 2021, the Company issued 2,936,668 200,000 2,630 On September 20, 2021, the Company issued 4,138,369 250,000 4,095 On October 4, 2021, the Company issued 2,957,622 200,000 2,301 On October 12, 2021, the Company issued 4,205,118 250,000 5,671 On October 25, 2021, the Company issued 3,043,955 200,000 1,205 On October 28, 2021, the Company issued a 7-year option to purchase 750,000 0.0785 On November 10, 2021, the Company issued 3,528,221 200,000 5,342 On November 22, 2021, the Company issued 3,561,885 200,000 1,603 On December 6, 2021, the Company issued 5,175,822 250,000 1,027 On December 21, 2021, the Company issued 5,874,062 250,000 35,479

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9 COMMITMENTS AND CONTINGENCIES On November 10, 2010, the Company entered into an employment agreement with its CEO, effective January 1, 2011 through the December 31, 2015. The term of the agreement is a five year period 210,000 6 281,027 20 5 297,889 5 315,764 5 422,561 3,077,393 2,991,191 On January 20, 2015, the board of directors appointed Mr. Jonathan R. Rice as our Chief Operating Officer. Mr. Rice’s employment agreement has a term of one year and can be terminated by either the Company or Mr. Rice at any time. Under the employment agreement, Mr. Rice is entitled to an annual cash compensation of $ 120,000 11,000 three 2,000,000 0.001 three 3,000,000 0.001 May 28, 2022 121,448 140,000 three 6,000,000 0.001 May 20, 2026 five 6,000,000 0.2299 20,000 20,000 20,000 As of December 31, 2022 and December 31, 2021, the Company owes $ 3,728 3,195 On July 3, 2019, the board of directors appointed Mr. Kenneth Le as the Company’s Director of Government relations and President of Prodigy Textiles. Mr. Le’s employment agreement has a term of one year and can be terminated by either the Company or Mr. Rice at any time. Under the employment agreement, Mr. Le is entitled to annual cash compensation of $ 60,000 three 2,000,000 0.2299 1,243 1,065 (A) License Agreement On May 8, 2006, the Company entered into a license agreement. Pursuant to the terms of the agreement, the Company paid a non- refundable license fee of $ 10,000 10,000 13,700 10,000 On October 28, 2011, the Company entered into a license agreement with the University of Notre Dame. Under the agreement, the Company received exclusive and non-exclusive rights to certain spider silk technologies including commercial rights with the right to sublicense such intellectual property. In consideration of the licenses granted under the agreement, the Company agreed to issue to the University of Notre Dame 2,200,000 2 20 The Company can terminate the agreement upon a 90 day written notice subject to payment of a termination fee of $ 5,000 265,244 4,025,652 281,659 60,000 On December 26, 2006, the Company entered into an addendum to the intellectual property transfer agreement with Mr. Thompson, its CEO. In accordance with FASB ASC No 480, Distinguishing Liabilities from Equity, 120,000 December 26, 2007 65,292 1,962 (B) Operating Lease Agreements Since September of 2015, we rent office space at 2723 South State Street, Suite 150, Ann Arbor, Michigan 48104, which is our principal place of business. We pay an annual rent of $ 2,508 On May 9, 2019, the Company signed a 5 4,560.57 45,150 5 Leases On July 1, 2021, the Company signed a 5 6,000 8,645 Leases On September 13, 2017, the Company signed a new two year lease with a 2 year option commencing on October 1, 2017 and ending on September 31, 2019. The Company paid an annual rent of $ 39,200 42,000 the Company signed a new two-year lease for this 5,000 square foot property in Lansing, MI that commenced on October 1, 2019 and ends on September 30, 2021, for its research and development headquarters 42,000 44,800 42,000 44,800 Leases On January 23, 2017 the Company signed an 8 960 0 3,683

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 10 RELATED PARTY TRANSACTIONS Accounts payable and accrued expenses – related party consists of the following: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES RELATED PARTY As of As of December 31, 2022 December 31, 2021 Accounts payable - related party $ 356,191 $ 347,156 Accrued expenses - related party 3,082,363 2,995,452 Accrued interest - related party 2,276,454 1,901,952 Total accounts payable and accrued expenses - related party $ 5,715,008 $ 5,244,560 June 6, 2016, the Company received a $ 50,000 30,000 100,000 15,000 20,000 15,000 15,000 20,000 26,000 11,000 20,000 3,000 30,000 30,000 20,000 20,000 17,000 100,000 100,000 100,000 100,000 100,000 100,000 150,000 100,000 100,000 100,000 30,000 30,000 35,000 70,000 3 On January 26, 2022, the Company repaid $ 40,000 Total loan payable to principal stockholder for as of December 31, 2022 is $ 1,617,000 Total loan payable to this principal stockholder as of December 31, 2021 is $ 1,657,000 During the year ended December 31, 2022, the Company recorded $ 80,849 as an in-kind contribution of interest related to the loan and recorded accrued interest payable of $ 54,755 As of December 31, 2022, total interest payable is $ 107,882 During the year ended September 30, 2021, the Company recorded $ 61,968 40,138 On January 23, 2017, the Company signed an 8 960 0 3,683 As of December 31, 2022, and December 31, 2021, there was $ 356,191 347,156 As of December 31, 2022, and December 31, 2021, there was $ 3,082,363 2,995,452 As of December 31, 2022, and December 31, 2021, there was $ 2,276,454 1,901,952 In aggregate as of December 31, 2022, and December 31, 2021, the Company owed $ 5,714,008 5,244,560

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 11 SUBSEQUENT EVENTS The Company has analyzed its operations subsequent to March 29, 2023 through the date these financial statements were issued, and has determined that, other than disclosed below, it does not have any material subsequent events to disclose. On February 16, 2023, the Company issued 2,434,211 2,500,000

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Policies)	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization On July 15, 2022, the Company signed an agreement with Global Silk Solutions Joint Stock Company (GSS). Under this agreement, GSS will serve as a contract manufacturer for the Company’s recombinant spider silk. Kraig Biocraft Laboratories, Inc. (the “Company”) was incorporated under the laws of the State of Wyoming on April 25, 2006. The Company was organized to develop high strength, protein based fiber, using recombinant DNA technology, for commercial applications in the textile and specialty fiber industries. Kraig Biocraft Laboratories, Inc. (the “Company”) was incorporated under the laws of the State of Wyoming on April 25, 2006. The Company was organized to develop high strength, protein based fiber, using recombinant DNA technology, for commercial applications in the textile and specialty fiber industries. On March 5, 2018, the Company issued a board resolution authorizing investment in a Vietnamese subsidiary and appointing a representative for the subsidiary. On April 24, 2018, the Company announced that it had received its investment registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd. On May 1, 2018, the Company announced that it had received its enterprise registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd
Foreign Currency	Foreign Currency The assets and liabilities of Prodigy Textiles, Co., Ltd. (the Company’s Vietnamese subsidiary) whose functional currency is the Vietnamese Dong, are translated into US dollars at period-end exchange rates prior to consolidation. Income and expense items are translated at the average rates of exchange prevailing during the period. The adjustments resulting from translating the Company’s financial statements are reflected as a component of other comprehensive (loss) income. Foreign currency transaction gains and losses are recognized in net earnings based on differences between foreign exchange rates on the transaction date and settlement date.
Use of Estimates	Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates.
Cash	Cash The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. There were no
Loss Per Share	Loss Per Share Basic and diluted net loss per common share is computed based upon the weighted average common shares outstanding as defined by the Financial Accounting Standards Board (“FASB” Accounting Standards Codification (“ASC”) No. 260, “Earnings per Share.” For December 31, 2022 and December 31, 2021, warrants were not included in the computation of income/ (loss) per share because their inclusion is anti-dilutive. The computation of basic and diluted loss per share for December 31, 2022 and 2021 excludes the common stock equivalents of the following potentially dilutive securities because their inclusion would be anti-dilutive: SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE December 31, 2022 December 31, 2021 Stock Warrants (Exercise price - $ 0.001 0.25 54,660,032 48,972,277 Stock Options (Exercise price - $ 0.1150 26,520,000 26,802,500 Convertible Debt - 6,470,674 Convertible Preferred Stock 2 2 Total 81,180,034 82,245,453
Research and Development Costs	Research and Development Costs The Company expenses all research and development costs as incurred for which there is no alternative future use. These costs also include the expensing of employee compensation and employee stock based compensation. For the the years ended December 31, 2022 and 2021, the Company had $ 176,431 197,745 Advertising Expense The Company follows the policy of charging the costs of advertising to expense as incurred. There was no advertising expense in the years ended December 31, 2022 and 2021.
Income Taxes	Income Taxes The Company accounts for income taxes under FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC No. 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC No. 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2022 2021 Expected income tax (recovery) expense at the statutory rate of 21 $ (806,823 ) $ (1,689,619 ) Tax effect of expenses that are not deductible for income tax purposes (net of other amounts deductible for tax purposes) 282,808 1,141,619 Change in valuation allowance 524,014 548,000 Provision for income taxes $ - $ - The components of deferred income taxes are as follows: SCHEDULE OF COMPONENTS DEFERRED INCOME TAXES 2022 2021 Years Ended December, 2022 2021 Deferred tax liability: $ - $ - Deferred tax asset Net Operating Loss Carryforward 4,887,351 4,363,336 Valuation allowance (4,887,351 ) (4,343,336 ) Net deferred tax asset - - Net deferred tax liability $ - $ - The valuation allowance was established to reduce the deferred tax asset to the amount that will more likely than not be realized. This is necessary due to the Company’s continued operating losses and the uncertainty of the Company’s ability to utilize all of the net operating loss carryforwards before they will expire through the year 2041. The net change in the valuation allowance for the year ended December 31, 2022 and 2021 was an increase of $ 524,014 548,000
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation for employees and directors in accordance with ASC 718, Compensation (“ASC 718”). ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Under the provisions of ASC 718, stock-based compensation costs are measured at the grant date, based on the fair value of the award, and are recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718 and, excess tax benefits realized from the exercise of stock-based awards are classified as cash flows from operating activities. All excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) are recognized as income tax expense or benefit in the condensed consolidated statements of operations. The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in ASU 2018-07.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Changes to accounting principles are established by the FASB in the form of ASU’s to the FASB’s Codification. We consider the applicability and impact of all ASU’s on our financial position, results of operations, stockholders’ deficit, cash flows, or presentation thereof. Management has evaluated all recent accounting pronouncements as issued by the FASB in the form of Accounting Standards Updates (“ASU”) through the date these financial statements were available to be issued and found no recent accounting pronouncements issued, but not yet effective accounting pronouncements, when adopted, will have a material impact on the financial statements of the Company. In September 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, Measurement of Credit Losses on Financial Instruments, which supersedes current guidance by requiring recognition of credit losses when it is probable that a loss has been incurred. The new standard requires the establishment of an allowance for estimated credit losses on financial assets including trade and other receivables at each reporting date. The new standard will result in earlier recognition of allowances for losses on trade and other receivables and other contractual rights to receive cash. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842), which extends the effective date of Topic 326 for certain companies until fiscal years beginning after December 15, 2022. The new standard will be effective for the Company in the first quarter of fiscal year beginning January 1, 2023, and early adoption is permitted. We adopted this pronouncement on January 1, 2021; however, the adoption of this standard did not have a material effect on the Company’s financial statements. In December 2019, the FASB issued ASU 2019-12, “Simplifying the Accounting for Income Taxes.” This guidance, among other provisions, eliminates certain exceptions to existing guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. This guidance also requires an entity to reflect the effect of an enacted change in tax laws or rates in its effective income tax rate in the first interim period that includes the enactment date of the new legislation, aligning the timing of recognition of the effects from enacted tax law changes on the effective income tax rate with the effects on deferred income tax assets and liabilities. Under existing guidance, an entity recognizes the effects of the enacted tax law change on the effective income tax rate in the period that includes the effective date of the tax law. ASU 2019-12 is effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted. We adopted this pronouncement on January 1, 2021; however, the adoption of this standard did not have a material effect on the Company’s financial statements. However, based on the Company’s history of immaterial credit losses from trade receivables, management does not expect that the adoption of this standard will have a material effect on the Company’s financial statements. In August 2020, FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity; Own Equity (“ASU 2020-06”), as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes from GAAP separation models for convertible debt that require the convertible debt to be separated into a debt and equity component, unless the conversion feature is required to be bifurcated and accounted for as a derivative or the debt is issued at a substantial premium. As a result, after adopting the guidance, entities will no longer separately present such embedded conversion features in equity and will instead account for the convertible debt wholly as debt. The new guidance also requires use of the “if-converted” method when calculating the dilutive impact of convertible debt on earnings per share, which is consistent with the Company’s current accounting treatment under the current guidance. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, but only at the beginning of the fiscal year. The Company adopted the guidance under ASU 2020-06 on January 1, 2022. The adoption of this guidance and had no material impact on the Company’s financial statements.
Equipment	Equipment The Company values property and equipment at cost and depreciates these assets using the straight-line method over their expected useful life. In accordance with FASB ASC No. 360, Property, Plant and Equipment, There were no
Fair Value of Financial Instruments	Fair Value of Financial Instruments We hold certain financial assets, which are required to be measured at fair value on a recurring basis in accordance with the Statement of Financial Accounting Standard No. 157, “Fair Value Measurements” The three levels of the fair value hierarchy under ASC Topic 820-10 are described below: ● Level 1 - Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. We believe our carrying value of level 1 instruments approximate their fair value at December 31, 2022 and 2021. ● Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. ● Level 3 - Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. We consider depleting assets, asset retirement obligations and net profit interest liability to be Level 3. We determine the fair value of Level 3 assets and liabilities utilizing various inputs, including NYMEX price quotations and contract terms. SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS December 31, 2022 December 31, 2021 Level 1 – Investment in Gold $ 437,251 $ 437,212 Level 2 $ - $ - Level 3 $ - $ - Total $ 437,251 $ 437,212 The Board of Directors, who serves as the Custodian, is responsible for the safekeeping of gold bullion owned by the Company. Fair value of the gold bullion held by the Company is based on that day’s London Bullion Market Association (“LBMA”) Gold Price PM. “LBMA Gold Price PM” is the price per fine troy ounce of gold, stated in U.S. dollars, determined by ICE Benchmark Administration (“IBA”) following an electronic auction consisting of one or more 30-second rounds starting at 3:00 p.m. (London time), on each day that the London gold market is open for business and published shortly thereafter. The following tables summarize activity in gold bullion for the quarter ended December 31, 2022: SCHEDULE OF GOLD IN BULLION Year Ended December 31, 2022 Ounces Cost Fair Value Beginning balance - $ - $ - Investment in Gold bullion 239 1,884 450,216 Net change in unrealized loss - - (13,004 ) Balance December 31, 2021 239 $ 1,884 $ 437,212 Net change in unrealized gain - 38 38 Balance December 31, 2022 239 $ 1,829 $ 437,251
Revenue Recognition	Revenue Recognition Effective January 1, 2018, the Company adopted ASC No. 606 — Revenue from Contracts with Customers. Under ASC No. 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the years ended December 31, 2022 and 2021, the Company recognized $ 0 0
Concentration of Credit Risk	Concentration of Credit Risk The Company at times has cash in banks in excess of FDIC insurance limits. At December 31, 2022 and December 31, 2021, the Company had approximately $ 3,285,197 2,092,420
Original Issue Discount	Original Issue Discount For certain notes issued, the Company provides the debt holder with an original issue discount. The original issue discount is recorded as a debt discount, reducing the face amount of the note, and is amortized to amortization of original issue discount in the consolidated statements of operations over the life of the debt.
Debt Issue Cost	Debt Issue Cost Debt issuance cost paid to lenders, or third parties are recorded as debt discounts and amortized to interest expense in the consolidated statements of operations, over the life of the underlying debt instrument.
Deposit	Deposit During the year ended December 31, 2022, the Company paid $ 98,480

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Tables)	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE	The computation of basic and diluted loss per share for December 31, 2022 and 2021 excludes the common stock equivalents of the following potentially dilutive securities because their inclusion would be anti-dilutive: SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE December 31, 2022 December 31, 2021 Stock Warrants (Exercise price - $ 0.001 0.25 54,660,032 48,972,277 Stock Options (Exercise price - $ 0.1150 26,520,000 26,802,500 Convertible Debt - 6,470,674 Convertible Preferred Stock 2 2 Total 81,180,034 82,245,453
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES	SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2022 2021 Expected income tax (recovery) expense at the statutory rate of 21 $ (806,823 ) $ (1,689,619 ) Tax effect of expenses that are not deductible for income tax purposes (net of other amounts deductible for tax purposes) 282,808 1,141,619 Change in valuation allowance 524,014 548,000 Provision for income taxes $ - $ -
SCHEDULE OF COMPONENTS DEFERRED INCOME TAXES	The components of deferred income taxes are as follows: SCHEDULE OF COMPONENTS DEFERRED INCOME TAXES 2022 2021 Years Ended December, 2022 2021 Deferred tax liability: $ - $ - Deferred tax asset Net Operating Loss Carryforward 4,887,351 4,363,336 Valuation allowance (4,887,351 ) (4,343,336 ) Net deferred tax asset - - Net deferred tax liability $ - $ -
SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS	SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS December 31, 2022 December 31, 2021 Level 1 – Investment in Gold $ 437,251 $ 437,212 Level 2 $ - $ - Level 3 $ - $ - Total $ 437,251 $ 437,212
SCHEDULE OF GOLD IN BULLION	The following tables summarize activity in gold bullion for the quarter ended December 31, 2022: SCHEDULE OF GOLD IN BULLION Year Ended December 31, 2022 Ounces Cost Fair Value Beginning balance - $ - $ - Investment in Gold bullion 239 1,884 450,216 Net change in unrealized loss - - (13,004 ) Balance December 31, 2021 239 $ 1,884 $ 437,212 Net change in unrealized gain - 38 38 Balance December 31, 2022 239 $ 1,829 $ 437,251

EQUIPMENT (Tables)

EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT	At December 31, 2022 and December 31, 2021, property and equipment, net, is as follows: SCHEDULE OF PROPERTY AND EQUIPMENT December 31, 2022 December 31, 2021 Estimated Useful Lives (Years) Automobile $ 41,805 $ 41,805 5 Laboratory Equipment 123,911 118,890 5 10 Office Equipment 7,260 7,260 5 10 Leasehold Improvements 82,739 82,739 2 5 Less: Accumulated Depreciation (167,854 ) (139,751 ) Total Property and Equipment, net $ 87,861 $ 110,943

RIGHT TO USE ASSETS AND LEASE_2

RIGHT TO USE ASSETS AND LEASE LIABILITITY (Tables)	12 Months Ended
	Dec. 31, 2022
Right To Use Assets And Lease Liabilitity
SCHEDULE OF OPERATING LEASES	At December 31, 2022 and 2021, the Company had no financing leases as defined in ASC 842, “Leases.” SCHEDULE OF OPERATING LEASES December 31, 2022 December 31, 2021 Assets Operating lease - right-of-use asset - non-current $ 58,849 $ 104,124 Liabilities Operating lease liability $ 59,897 $ 104,124 Weighted-average remaining lease term (years) 2.08 2.69 Weighted-average discount rate 8 % 8 % The components of lease expense were as follows: Operating lease costs Amortization of right-of-use operating lease asset $ 52,043 $ 96,978 Total operating lease costs $ 52,043 $ 96,978 Supplemental cash flow information related to operating leases was as follows: Operating cash outflows from operating lease (obligation payment) $ 51,344 $ 130,147 Right-of-use asset obtained in exchange for new operating lease liability $ - $ 115,389
SCHEDULE OF MINIMUM LEASE PAYMENTS	Future minimum lease payments required under leases that have initial or remaining non-cancelable lease terms in excess of one year at December 31, 2022: SCHEDULE OF MINIMUM LEASE PAYMENTS 2023 $ 42,242 2024 8,644 2025 8,644 2026 5,763 Total lease payments 65,294 Less: amount representing interest (5,397 ) Total lease obligations 59,897 Less: current portion of operating lease liability (39,200 ) Long-term portion operating lease liability $ 20,697

CONVERTIBLE NOTES (Tables)

CONVERTIBLE NOTES (Tables)	12 Months Ended
	Dec. 31, 2022
Convertible Notes
SCHEDULE OF FAIR VALUE WARRANTS	SCHEDULE OF FAIR VALUE WARRANTS Stock Price $ 0.14 Exercise price $ 0.16 Expected term (in years) 5 Expected volatility 60.64 % Annual rate of quarterly dividends 0 % Risk free interest rate 0.10 % Stock Price $ 0.15 Exercise price $ 0.25 Expected term (in years) 5 Expected volatility 100.76 % Annual rate of quarterly dividends 0 % Risk free interest rate 0.07 % Stock Price $ 0.08 Exercise price $ 0.12 Exercise price $ 0.14 Expected term (in years) 5 Expected volatility 124.10 % Annual rate of quarterly dividends 0 % Risk free interest rate 0.58 %
SUMMARY OF CONVERTIBLE DEBT	The following represents a summary of the Company’s convertible debt at December 31, 2022: SUMMARY OF CONVERTIBLE DEBT Convertible Note Payable Amounts In-Default Balance – December 31, 2020 $ 50,505 - Proceeds 4,000,000 Debt discount recorded (4,000,000 ) Conversion of debt into common shares (4,250,000 ) Amortization of debt discount 4,702,918 Balance – December 31, 2021 $ 503,423 $ - Proceeds 3,000,000 - Debt discount and issue costs recorded (865,000 )              - Conversion of debt into common shares (3,750,003 ) Amortization of debt discount 1,111,580 - Balance – December 31, 2022 $ - $ - Accrued Interest Payable Amounts In-Default Balance – December 31, 2020 $ 5,479 - Interest Expense 2021 238,110 Interest conversion into common shares (211,932 ) Balance – December 31, 2021 31,657 $ - Interest Expense December 31, 2022 153,955               - Interest conversion into common shares (185,612 ) Balance – December 31, 2022 $ - $ -

STOCKHOLDERS_ DEFICIT (Tables)

STOCKHOLDERS’ DEFICIT (Tables)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
SCHEDULE OF OPTION ASSUMPTION	SCHEDULE OF OPTION ASSUMPTION Expected dividends 0 % Expected volatility 133.22 % Expected term 7 Risk free interest rate 1.46 % Expected forfeitures 0 % Expected dividends 0 % Expected volatility 125.19 % Expected term 3 Risk free interest rate 1.50 % Expected forfeitures 0 % Expected dividends 0 % Expected volatility 125.19 % Expected term 6 Risk free interest rate 1.46 % Expected forfeitures 0 %
SCHEDULE OF WARRANTS ACTIVITY	Warrant activity for the years ended December 31, 2022 and 2021 are summarized as follows: SCHEDULE OF WARRANTS ACTIVITY Weighted Average Weighted Remaining Aggregate Warrants Number of Warrants Average Exercise Price Contractual Term (Years) Intrinsic Value Outstanding - December 31, 2020 49,120,917 $ 0.14 1.83 $ 3,013,010 Exercisable - December 31, 2020 49,120,917 $ 0.14 1.83 $ 3,013,010 Granted 8,500,000 $ 0.24 4.19 - Exercised (5,439,184 ) $ 0.06 4 - Cancelled/Forfeited (4,209,456 ) $ 0.07 - - Outstanding - December 31, 2021 48,972,279 $ 0.12 2.64 $ 1,248,452 Exercisable - December 31, 2021 48,972,279 $ 0.12 2.64 $ 1,248,452 Granted 16,785,714 $ 0.12 4.05 - Exercised (11,097,959 ) $ 0.07 - - Cancelled/Forfeited - $ - - - Outstanding - December 31, 2022 54,660,034 $ 0.13 3.04 $ 319,000 Exercisable - December 31, 2022 54,660,034 $ 0.13 3.04 $ 319,000
SCHEDULE OF OPTIONS ACTIVITY	For the year ended December 31, 2022, the following warrants were outstanding: SCHEDULE OF WARRANTS OUTSTANDING Exercise Price Warrants Weighted Average Aggregate $ 0.001 11,000,000 3.43 $ 321,000 $ 0.04 2,300,000 3.75 $ - $ 0.08 3,699,320 0.18 $ - $ 0.2299 8,250,000 2.21 $ - $ 0.16 3,125,000 2.95 $ - $ 0.25 8,000,000 3.23 $ - $ 0.1160 500,000 2.52 $ - $ 0.12 12,500,000 4.05 $ - $ 0.14 4,285,714 4.05 $ - For the year ended December 31, 2021, the following warrants were outstanding: Exercise Price Warrants Weighted Average Aggregate $ 0.001 11,000,000 3.07 $ 913,900 $ 0.056 1,000,000 3.52 $ 27,900 $ 0.04 2,300,000 4.75 $ 100,970 $ 0.06 7,398,639 0.18 $ 176,827 $ 0.08 3,699,320 0.18 $ 14,427 $ 0.08 3,699,320 1.18 $ 14,427 $ 0.2299 8,250,000 3.21 $ - $ 0.16 3,125,000 4.95 $ - $ 0.25 8,000,000 4.23 $ - $ 0.1160 500,000 3.52 $ - Options activity for the years ended December 31, 2022 and 2021 are summarized as follows: SCHEDULE OF OPTIONS ACTIVITY Options Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding - December 31, 2020 27,340,000 $ 0.12 22.60 $ - Exercisable - December 31, 2020 27,340,000 $ 0.12 22.60 $ - Granted 2,500,000 $ 0.13 6.07 - Exercised (2,200,000 ) $ 0.12 9.00 - Cancelled/Forfeited (837,500 ) $ 0.12 6.00 - Outstanding - December 31, 2021 26,802,500 $ 0.12 19.12 $ - Exercisable - December 31, 2021 26,802,500 $ 0.12 19.12 $ - Granted - $ - - - Exercised - $ - - - Cancelled/Forfeited (282,500 ) $ 0.12 5.00 - Outstanding - December 31, 2022 26,520,000 $ 0.12 18.27 $ - Exercisable - December 31, 2022 26,520,000 $ 0.12 18.27 $ -
SCHEDULE OF OPTIONS ACTIVITY	Options activity for the years ended December 31, 2022 and 2021 are summarized as follows: SCHEDULE OF OPTIONS ACTIVITY Options Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding - December 31, 2020 27,340,000 $ 0.12 22.60 $ - Exercisable - December 31, 2020 27,340,000 $ 0.12 22.60 $ - Granted 2,500,000 $ 0.13 6.07 - Exercised (2,200,000 ) $ 0.12 9.00 - Cancelled/Forfeited (837,500 ) $ 0.12 6.00 - Outstanding - December 31, 2021 26,802,500 $ 0.12 19.12 $ - Exercisable - December 31, 2021 26,802,500 $ 0.12 19.12 $ - Granted - $ - - - Exercised - $ - - - Cancelled/Forfeited (282,500 ) $ 0.12 5.00 - Outstanding - December 31, 2022 26,520,000 $ 0.12 18.27 $ - Exercisable - December 31, 2022 26,520,000 $ 0.12 18.27 $ -
SCHEDULE OF OPTIONS OUTSTANDING	For the year ended December 31, 2022, the following options were outstanding: SCHEDULE OF OPTIONS OUTSTANDING Weighted Average Exercise Options Options Remaining Price Outstanding Exercisable Contractual Life (in Years) $ 0.115 - 26,520,000 18.52 For the year ended December 31, 2021, the following options were outstanding: Weighted Average Exercise Options Options Remaining Price Outstanding Exercisable Contractual Life (in Years) $ 0.115 - 26,802,500 19.11

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES RELATED PARTY	Accounts payable and accrued expenses – related party consists of the following: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES RELATED PARTY As of As of December 31, 2022 December 31, 2021 Accounts payable - related party $ 356,191 $ 347,156 Accrued expenses - related party 3,082,363 2,995,452 Accrued interest - related party 2,276,454 1,901,952 Total accounts payable and accrued expenses - related party $ 5,715,008 $ 5,244,560

SCHEDULE OF ANTIDILUTIVE SECURI

SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	81,180,034	82,245,453
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	54,660,032	48,972,277
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	26,520,000	26,802,500
Convertible Debt [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		6,470,674
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	2	2

SCHEDULE OF ANTIDILUTIVE SECU_2

SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE (Details) (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Option exercise price	$ 0.1150	$ 0.1150
Minimum [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Warrant exercise price per share	0.06
Maximum [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Warrant exercise price per share	0.08
Warrant [Member] | Minimum [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Warrant exercise price per share	0.001	0.001
Stock Warrants [Member] | Maximum [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Warrant exercise price per share	$ 0.25	$ 0.25

SCHEDULE OF DEFERRED TAX ASSETS

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Expected income tax (recovery) expense at the statutory rate of 21%	$ (806,823)	$ (1,689,619)
Tax effect of expenses that are not deductible for income tax purposes (net of other amounts deductible for tax purposes)	282,808	1,141,619
Change in valuation allowance	524,014	548,000
Provision for income taxes

SCHEDULE OF DEFERRED TAX ASSE_2

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) (Parenthetical)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Statutory rate	21%	21%

SCHEDULE OF COMPONENTS DEFERRED

SCHEDULE OF COMPONENTS DEFERRED INCOME TAXES (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Deferred tax liability:
Deferred tax asset
Net Operating Loss Carryforward	4,887,351	4,363,336
Valuation allowance	(4,887,351)	(4,343,336)
Net deferred tax asset
Net deferred tax liability

SCHEDULE OF FAIR VALUE OF FINAN

SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets and liabilities	$ 437,251	$ 437,212
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets and liabilities	437,251	437,212
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets and liabilities
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets and liabilities

SCHEDULE OF GOLD IN BULLION (De

SCHEDULE OF GOLD IN BULLION (Details)	12 Months Ended
	Dec. 31, 2022 USD ($) oz	Dec. 31, 2021 USD ($) oz
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Beginning balalnce, ounce | oz	239
Beginning balalnce, cost	$ 1,884
Beginning balalnce, fair value	437,212
Investments in gold bullion, ounce | oz		239
Investments in gold bullion, cost		$ 1,884
Investment in Gold bullion, fair value		$ 450,216
Net change in unrealized depreciation, ounce | oz
Net change in unrealized depreciation, cost
Net change in unrealized depreciation, fair value		$ (13,004)
Net change in unrealized loss, ounce | oz
Net change in unrealized loss, cost	$ 38
Net change in unrealized loss, fair value	$ 38
Ending balance, ounce | oz	239	239
Ending balance, cost	$ 1,829	$ 1,884
Ending balance, fair value	$ 437,251	$ 437,212

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash equivalents	$ 0	$ 0
Research and development costs	176,431	197,745
Valuation allowance increase decrease	524,014	548,000
Impairment losses on equipment	0	0
Revenue
Cash excess of FDIC insurance limits	3,285,197	2,092,420
Deposits	$ 98,480

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Working capital deficit	$ 4,088,642
Stockholders' deficiency	3,521,860	$ 5,295,875	$ 6,573,564
Cash used in operating activities	$ 1,887,187	$ 1,800,809

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Less: Accumulated Depreciation	$ (167,854)	$ (139,751)
Total Property and Equipment, net	87,861	110,943
Automobiles [Member]
Property, Plant and Equipment [Line Items]
Leasehold Improvements	$ 41,805	41,805
Estimated Useful Lives (Years)	5 years
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Leasehold Improvements	$ 123,911	118,890
Laboratory Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Lives (Years)	5 years
Laboratory Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Lives (Years)	10 years
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Leasehold Improvements	$ 7,260	7,260
Office Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Lives (Years)	5 years
Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Lives (Years)	10 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Leasehold Improvements	$ 82,739	$ 82,739
Leasehold Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Lives (Years)	2 years
Leasehold Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Lives (Years)	5 years

EQUIPMENT (Details Narrative)

EQUIPMENT (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 28,103	$ 26,137

SCHEDULE OF OPERATING LEASES (D

SCHEDULE OF OPERATING LEASES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Jul. 02, 2021
Right To Use Assets And Lease Liabilitity
Operating lease - right-of-use asset - non-current	$ 58,849	$ 104,124	$ 241,800
Operating lease liability	$ 59,897	$ 104,124
Weighted-average remaining lease term (years)	2 years 29 days	2 years 8 months 8 days
Weighted-average discount rate	8%	8%
Amortization of right-of-use operating lease asset	$ 52,043	$ 96,978
Total operating lease costs	52,043	96,978
Operating cash outflows from operating lease (obligation payment)	51,344	130,147
Right-of-use asset obtained in exchange for new operating lease liability		$ 115,389

SCHEDULE OF MINIMUM LEASE PAYME

SCHEDULE OF MINIMUM LEASE PAYMENTS (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021	Sep. 05, 2019	Sep. 13, 2017
Right To Use Assets And Lease Liabilitity
2023	$ 42,242		$ 42,000	$ 39,200
2024	8,644		$ 44,800	$ 42,000
2025	8,644
2026	5,763
Total lease payments	65,294
Less: amount representing interest	(5,397)
Total lease obligations	59,897	$ 104,124
Less: current portion of operating lease liability	(39,200)	(44,577)
Long-term portion operating lease liability	$ 20,697	$ 59,897

RIGHT TO USE ASSETS AND LEASE_3

RIGHT TO USE ASSETS AND LEASE LIABILITITY (Details Narrative)				3 Months Ended		12 Months Ended
	Jul. 01, 2021 USD ($) m²	May 09, 2019 USD ($) m²	Jan. 23, 2017 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jul. 02, 2021 USD ($) m²	Apr. 05, 2021 USD ($)	Sep. 05, 2019 USD ($) ft²	Sep. 13, 2017 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lease liabilities				$ 39,200	$ 44,577	$ 39,200	$ 44,577
Lease term										2 years
Area of land | ft²										5,000
Annual rent, year one				42,242		42,242				$ 42,000	$ 39,200
Annual rent, year two				8,644		8,644				$ 44,800	$ 42,000
Operating lease, right-of-use asset				58,849	104,124	58,849	104,124	$ 241,800
Socialist Republic of Vietnam [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lease term		5 years						5 years
Area of land | m²		4,560.57						6,000
Annual rent, year one								$ 8,645
Annual rent, year two		$ 45,150
Rent increase percentage		5%
Operating Lease Agreements [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Rent payments						2,508
Operating Lease Agreements [Member] | Socialist Republic of Vietnam [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Rent payments	$ 8,645	$ 45,150
Operating Lease	5 years	5 years
Area of land | m²	6,000	4,560.57
Rent increase percentage		5%
Operating Lease Agreements [Member] | October 1, 2022 through September 30, 2023 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Rent payments						44,800
Operating Lease Agreements [Member] | Office and Manufacturing Space [Member] | July 1, 2021 and ending on September 30, 2022 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Rent payments						42,000
Operating Lease Agreements [Member] | President [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Rent payments			$ 960	0	$ 3,683	0	$ 3,683
Operating Lease			8 years
Removal of New Guidance [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lease liabilities									$ 44,419
Adoption of New Guidance [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lease liabilities				79,862		79,862
Operating lease, right-of-use asset				$ 79,862		$ 79,862

NOTE PAYABLE _ RELATED PARTY (D

NOTE PAYABLE – RELATED PARTY (Details Narrative) - USD ($)																																9 Months Ended	12 Months Ended
	Dec. 01, 2020	Nov. 17, 2020	Nov. 04, 2020	Oct. 19, 2020	Sep. 10, 2020	Aug. 12, 2020	Jul. 16, 2020	Jun. 03, 2020	Apr. 08, 2020	Mar. 09, 2020	Feb. 19, 2020	Jan. 24, 2020	Dec. 18, 2019	Nov. 20, 2019	Mar. 01, 2019	Feb. 15, 2019	Feb. 01, 2019	Jan. 17, 2019	Jan. 04, 2019	Jan. 04, 2019	Dec. 21, 2018	Oct. 12, 2018	Oct. 01, 2018	Jul. 05, 2018	Jun. 29, 2018	Jun. 21, 2018	Apr. 26, 2018	Mar. 31, 2018	Jan. 08, 2018	Dec. 01, 2017	Jun. 06, 2016	Sep. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Jan. 26, 2022
Short-Term Debt [Line Items]
Proceeds from issuance of debt	$ 70,000	$ 35,000	$ 30,000	$ 30,000	$ 100,000	$ 100,000	$ 100,000	$ 150,000	$ 100,000	$ 100,000	$ 100,000	$ 100,000	$ 100,000	$ 100,000	$ 20,000	$ 20,000	$ 30,000	$ 30,000	$ 3,000		$ 20,000	$ 11,000	$ 26,000	$ 20,000	$ 15,000	$ 15,000	$ 20,000	$ 15,000	$ 100,000	$ 30,000	$ 50,000
Debt instrument, interest rate, stated percentage																															3%
Notes payable, related parties, current																																	$ 1,617,000	$ 1,657,000	$ 40,000
Paid-in-kind interest																																$ 61,968	80,849	82,851
Interest payable																																	$ 54,755	$ 53,671
Loan One [Member]
Short-Term Debt [Line Items]
Proceeds from issuance of debt																				$ 17,000

LOAN PAYABLE (Details Narrative

LOAN PAYABLE (Details Narrative) - USD ($)		12 Months Ended
	Mar. 01, 2019	Dec. 31, 2022	Dec. 31, 2021	Jul. 08, 2021	Jun. 06, 2016
Short-Term Debt [Line Items]
Notes payable		$ 115,244		$ 180,244
Debt Instrument, Interest Rate, Stated Percentage					3%
Repayments of debt		60,000	$ 50,000
Loan balance		95,244	$ 60,000
First Nine Months [Member]
Short-Term Debt [Line Items]
Repayments of debt		1,000
Seven and Eight Months [Member]
Short-Term Debt [Line Items]
Repayments of debt		2,000
Nine Through Twenty Three Months [Member]
Short-Term Debt [Line Items]
Repayments of debt		5,000
24th Month [Member]
Short-Term Debt [Line Items]
Notes payable		180,224
13 Months [Member]
Short-Term Debt [Line Items]
Repayments of debt		5,000
14 Months [Member]
Short-Term Debt [Line Items]
Repayments of debt		57,622
20 Months [Member]
Short-Term Debt [Line Items]
Repayments of debt		57,622
Unsecured Debt [Member]
Short-Term Debt [Line Items]
Repayments of debt		$ 60,000
Notre Dame [Member] | Unsecured Debt [Member]
Short-Term Debt [Line Items]
Notes payable	$ 265,244
Debt Instrument, Interest Rate, Stated Percentage	10%
Debt Instrument, Description	The term of the loan is twenty-four months

SCHEDULE OF FAIR VALUE WARRANTS

SCHEDULE OF FAIR VALUE WARRANTS (Details)	Jan. 18, 2022 $ / shares	Mar. 25, 2021 $ / shares	Dec. 11, 2020 $ / shares
Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input, percentage	0.08	0.15	0.14
Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input, percentage		0.25	0.16
Measurement Input, Exercise Price [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input, percentage	0.12
Measurement Input, Exercise Price [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input, percentage	0.14
Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants term	5 years	5 years	5 years
Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input, percentage	124.10	100.76	60.64
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input, percentage	0	0	0
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input, percentage	0.58	0.07	0.10

SUMMARY OF CONVERTIBLE DEBT (De

SUMMARY OF CONVERTIBLE DEBT (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Balance, beginning	$ 503,423
Proceeds - net	2,760,000	$ 3,670,000
Balance, beginning		503,423
Balance, beginning	31,657	5,479
Balance beginning, accrued interest in-default
Interest expense	153,955	238,110
Interest conversion into common shares	(185,612)	(211,932)
Balance, ending		31,657
Balance ending accrued interest in-default
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Balance, beginning	503,423	50,505
Balance, In-Default
Proceeds - net	3,000,000	4,000,000
Debt discount and issue costs recorded	$ (865,000)	$ (4,000,000)
Conversion of debt into common shares	(3,750,003)	(4,250,000)
Amortization of debt discount	$ 1,111,580	$ 4,702,918
Balance, beginning		503,423
Balance, In-Default

CONVERTIBLE NOTES (Details Narr

CONVERTIBLE NOTES (Details Narrative)																																																		12 Months Ended
	Nov. 17, 2022 USD ($) shares	Nov. 14, 2022 USD ($) shares	Nov. 01, 2022 USD ($) shares	Oct. 31, 2022 USD ($) shares	Oct. 26, 2022 USD ($) shares	Oct. 18, 2022 USD ($) shares	Oct. 11, 2022 USD ($) shares	Sep. 26, 2022 USD ($) shares	Sep. 08, 2022 USD ($) shares	Aug. 18, 2022 USD ($) shares	Jul. 19, 2022 USD ($) shares	Jun. 30, 2022 USD ($) shares	Jun. 21, 2022 USD ($) shares	Jun. 14, 2022 USD ($) shares	Jun. 06, 2022 USD ($) shares	May 17, 2022 USD ($) shares	Apr. 29, 2022 USD ($) shares	Apr. 14, 2022 USD ($) shares	Apr. 11, 2022 USD ($)	Feb. 16, 2022 USD ($) shares	Feb. 16, 2022 USD ($) shares	Jan. 31, 2022 USD ($) shares	Jan. 21, 2022 USD ($) shares	Jan. 18, 2022 USD ($) $ / shares shares	Dec. 21, 2021 USD ($) shares	Dec. 06, 2021 USD ($) shares	Nov. 22, 2021 USD ($) shares	Nov. 10, 2021 USD ($) shares	Oct. 25, 2021 USD ($) shares	Oct. 12, 2021 USD ($) shares	Oct. 04, 2021 USD ($) shares	Sep. 20, 2021 USD ($) shares	Sep. 14, 2021 USD ($) shares	Sep. 08, 2021 USD ($) shares	Aug. 30, 2021 USD ($) shares	Aug. 23, 2021 USD ($) shares	Aug. 16, 2021 USD ($) shares	Jul. 29, 2021 USD ($) shares	Jul. 06, 2021 USD ($) shares	Jun. 23, 2021 USD ($) shares	Jun. 20, 2021 USD ($) shares	Jun. 07, 2021 USD ($) shares	Apr. 30, 2021 USD ($) shares	Apr. 26, 2021 USD ($) shares	Apr. 23, 2021 USD ($) shares	Apr. 22, 2021 USD ($)	Apr. 06, 2021 USD ($)	Mar. 25, 2021 USD ($) $ / shares shares	Dec. 11, 2020 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($)	Feb. 15, 2022 shares	Sep. 30, 2021 USD ($)	May 04, 2021 shares	Mar. 02, 2021 shares	Jun. 06, 2016
Debt Instrument [Line Items]
Debt instrument, interest rate																																																								3%
Proceeds from convertible note payable, net of original issue discount																																																		$ 2,760,000	$ 3,670,000
Number of warrants issued | shares																										1,479,728																										7,398,639		1,479,728	1,479,728
Debt instrument, discount																																																		0	$ 246,577
Interest payable																																																		54,755			$ 40,138
Issuance of convertible securities																																																		$ 3,935,615
Common Stock [Member]
Debt Instrument [Line Items]
Debt conversion, converted instrument, amount	$ 150,000	$ 150,000	$ 250,000	$ 150,000	$ 150,000	$ 150,000	$ 100,000	$ 150,000	$ 150,000	$ 200,000	$ 200,000	$ 150,000	$ 150,000	$ 100,000	$ 200,000	$ 200,000	$ 250,000	$ 150,000		$ 250,000	$ 250,000	$ 250,000	$ 250,000		$ 250,000	$ 250,000	$ 200,000	$ 200,000	$ 200,000	$ 250,000	$ 200,000	$ 250,000	$ 200,000	$ 250,000	$ 150,000	$ 200,000	$ 150,000	$ 200,000	$ 200,000	$ 200,000	$ 100,000	$ 200,000	$ 250,000	$ 250,000	$ 100,000
Number of warrants issued | shares																																																				3,699,320
Debt conversion, converted instrument, shares issued | shares	5,935,350	5,974,335	9,236,212	6,510,348	5,487,951	4,782,778	2,907,240	3,605,259	3,396,898	4,325,913	4,364,987	3,401,877	3,393,979	2,902,922	3,549,793	3,628,325	4,272,417	2,358,380		3,924,443	3,924,443	4,569,059	3,935,417		5,874,062	5,175,822	3,561,885	3,528,221	3,043,955	4,205,118	2,957,622	4,138,369	2,936,668	4,311,269	2,284,808	3,454,203	2,277,273	3,101,546	2,343,919	2,422,195	1,664,823	2,431,506	2,058,686	2,063,391	836,574
Interest payable	$ 164	$ 1,151	$ 301	$ 28,384	$ 370	$ 658	$ 1,753	$ 2,863	$ 4,219	$ 7,644	$ 6,027	$ 3,425	$ 3,068	$ 60,822	$ 5,178	$ 5,726	$ 5,918	$ 1,644		$ 1,164	$ 1,164	$ 42,877	$ 2,260		$ 35,479	$ 1,027	$ 1,603	$ 5,342	$ 1,205	$ 5,671	$ 2,301	$ 4,095	$ 2,630	$ 6,521	$ 3,082	$ 11,397	$ 6,904	$ 11,836	$ 7,671	$ 10,247	$ 60,822	$ 25,644	$ 3,630	$ 3,178	$ 1,644
Debt issuance cost																																											$ 338,654
Measurement Input, Share Price [Member]
Debt Instrument [Line Items]
Warrants, measurement input, percentage | $ / shares																								0.08																								0.15	0.14
Measurement Input, Exercise Price [Member]
Debt Instrument [Line Items]
Warrants, measurement input, percentage | $ / shares																																																0.25	0.16
Measurement Input, Expected Term [Member]
Debt Instrument [Line Items]
Warrants term																								5 years																								5 years	5 years
Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Warrants, measurement input, percentage																								124.10																								100.76	60.64
Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Warrants, measurement input, percentage																								0																								0	0
Measurement Input, Risk Free Interest Rate [Member]
Debt Instrument [Line Items]
Warrants, measurement input, percentage																								0.58																								0.07	0.10
Unsecured Convertible Note [Member]
Debt Instrument [Line Items]
Debt conversion, converted instrument, amount																								$ 1,500,000																								$ 4,000,000	$ 1,000,000
Debt instrument term																			13 months					13 months																								1 year	13 months
Debt instrument, interest rate																			10%					10%																									10%
Percentage of original issue discount																																																	5%
Original issue discount																								$ 10,000																									$ 50,000
Proceeds from convertible note payable, net of original issue discount																								$ 1,490,000																									$ 950,000
Debt instrument, description																			The note contains a discount to market feature, whereby, the lender can purchase stock at 85% of the lowest trading price for a period of ten (10) days preceding the conversion date					The note contains a discount to market feature, whereby, the lender can purchase stock at 85% of the lowest trading price for a period of ten (10) days preceding the conversion date																									The note contains a discount to market feature, whereby, the lender can purchase stock at 90% of the lowest trading price for a period of ten (10) days preceding the conversion date
Number of warrants issued | shares																								12,000,000																								8,000,000	3,125,000	4,285,714
Warrants term																																																5 years	5 years	5 years
Fair value adjustments of warrants																								$ 1,071,437																								$ 3,359,716	$ 2,599,066
Debt instrument, discount																																																3,670,000
Debt issuance costs																			$ 115,000					$ 115,000																								330,000	86,000
Debt instrument, maturity date																			May 11, 2023					Feb. 18, 2023
Exercise price | $ / shares																								$ 0.12																										$ 0.14
Issuance of convertible securities																			$ 1,500,000					$ 1,500,000
Class of warrant issued | shares																								16,785,714
Debt issuance cost																								$ 625,003
Unsecured Convertible Note [Member] | First Convertible Debenture [Member]
Debt Instrument [Line Items]
Debt conversion, converted instrument, amount																																																$ 500,000
Debt instrument, interest rate																																																10%
Debt instrument, description																																																The note contains a discount to market feature, whereby, the lender can purchase stock at 80% of the lowest trading price for a period of ten (10) days preceding the conversion date
Debt instrument, discount																																																	$ 1,000,000
Debt instrument, maturity date																																																Mar. 25, 2022
Unsecured Convertible Note [Member] | Second Convertible Debenture [Member]
Debt Instrument [Line Items]
Debt conversion, converted instrument, amount																																															$ 500,000
Unsecured Convertible Note [Member] | Third Convertible Debenture [Member]
Debt Instrument [Line Items]
Debt conversion, converted instrument, amount																																														$ 3,000,000

SCHEDULE OF OPTION ASSUMPTION (

SCHEDULE OF OPTION ASSUMPTION (Details)	Jan. 25, 2021	Feb. 19, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected dividends	0%	0%
Expected volatility	133.22%	125.19%
Expected term	7 years	3 years
Risk free interest rate	1.46%	1.50%
Expected forfeitures	0%	0%
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected dividends		0%
Expected volatility		125.19%
Expected term		6 years
Risk free interest rate		1.46%
Expected forfeitures		0%

SCHEDULE OF WARRANTS ACTIVITY (

SCHEDULE OF WARRANTS ACTIVITY (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Number of Warrants, Outstanding, Beginning balance	48,972,279	49,120,917
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 0.12	$ 0.14
Weighted Average Remaining Contractual Life (In Years)	3 years 14 days	2 years 7 months 20 days	1 year 9 months 29 days
Aggregate Intrinsic Value, Outstanding, Beginning balance	$ 1,248,452	$ 3,013,010
Number of Warrants, Exercisable, Beginning balance	48,972,279	49,120,917
Weighted Average Exercise Price, Exercisable, Beginning balance	$ 0.12	$ 0.14
Weighted Average Remaining Contractual Life (In Years)	3 years 14 days	2 years 7 months 20 days	1 year 9 months 29 days
Aggregate Intrinsic Value, Exercisable, Beginning balance	$ 1,248,452	$ 3,013,010
Number of Warrants, Granted	16,785,714	8,500,000
Weighted Average Exercise Price, Granted	$ 0.12	$ 0.24
Weighted Average Remaining Contractual Life (In Years), Granted		4 years 18 days	4 years 2 months 8 days
Number of Warrants, Exercised	(11,097,959)	(5,439,184)
Weighted Average Exercise Price, Exercised	$ 0.07	$ 0.06
Weighted Average Remaining Contractual Life (In Years), Exercised			4 years
Number of Warrants, Cancelled/Forfeited		(4,209,456)
Weighted Average Exercise Price, Cancelled/Forfeited		$ 0.07
Number of Warrants, Outstanding, Ending balance	54,660,034	48,972,279	49,120,917
Weighted Average Exercise Price, Outstanding, Ending balance	$ 0.13	$ 0.12	$ 0.14
Aggregate Intrinsic Value, Outstanding, Ending balance	$ 319,000	$ 1,248,452	$ 3,013,010
Number of Warrants, Exercisable, Ending balance	54,660,034	48,972,279	49,120,917
Weighted Average Exercise Price, Exercisable, Ending balance	$ 0.13	$ 0.12	$ 0.14
Aggregate Intrinsic Value, Exercisable, Ending balance	$ 319,000	$ 1,248,452	$ 3,013,010

SCHEDULE OF OPTIONS ACTIVITY (D

SCHEDULE OF OPTIONS ACTIVITY (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 30, 2022	Dec. 30, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants Exercisable	54,660,034	48,972,279	49,120,917
Aggregate Intrinsic Value	$ 319,000	$ 1,248,452	$ 3,013,010
Aggregate Intrinsic Value
Number of Options, Outstanding, Beginning balance	26,802,500	27,340,000
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 0.12	$ 0.12
Weighted Average Remaining Contractual Life (In Years)	18 years 3 months 7 days	19 years 1 month 13 days	22 years 7 months 6 days
Number of Options, Outstanding, Exercisable	26,802,500	27,340,000
Weighted Average Exercise Price, Outstanding, Exercisable	$ 0.12	$ 0.12
Weighted Average Remaining Contractual Life (In Years), Exercisable	18 years 3 months 7 days	19 years 1 month 13 days	22 years 7 months 6 days
Aggregate Intrinsic Value, Exercisable, Beginning balance
Number of Options, Outstanding, Granted		2,500,000
Weighted Average Exercise Price, Outstanding, Granted		$ 0.13
Weighted Average Remaining Contractual Life (In Years), Granted		6 years 25 days
Aggregate Intrinsic Value, Exercisable, Granted
Number of Options, Outstanding, Exercised		(2,200,000)
Weighted Average Exercise Price, Outstanding, Exercised		$ 0.12
Weighted Average Remaining Contractual Life (In Years), Exercised		9 years
Aggregate Intrinsic Value, Exercisable, Exercised
Number of Options, Outstanding, Cancelled/Forfeited	(282,500)	(837,500)
Weighted Average Exercise Price, Outstanding, Cancelled/Forfeited	$ 0.12	$ 0.12
Weighted Average Remaining Contractual Life (In Years), Cancelled/Forfeited	5 years	6 years
Aggregate Intrinsic Value, Exercisable, Cancelled/Forfeited
Number of Options, Outstanding, Exercised		2,200,000
Number of Options, Outstanding, Ending balance	26,520,000	26,802,500	27,340,000
Weighted Average Exercise Price, Outstanding, Ending balance	$ 0.12	$ 0.12	$ 0.12
Aggregate Intrinsic Value
Number of Options, Outstanding, Exercisable	26,520,000	26,802,500	27,340,000
Weighted Average Exercise Price, Outstanding, Exercisable	$ 0.12	$ 0.12	$ 0.12
Aggregate Intrinsic Value, Exercisable, Ending balance
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price	$ 0.001	$ 0.001
Warrants Exercisable	11,000,000	11,000,000
Weighted Average Remaining Contractual Life	3 years 5 months 4 days	3 years 25 days
Aggregate Intrinsic Value	$ 321,000
Aggregate Intrinsic Value		$ 913,900
Aggregate Intrinsic Value	$ 913,900
Aggregate Intrinsic Value		$ 913,900
Warrant One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price	$ 0.04	$ 0.056
Warrants Exercisable	2,300,000	1,000,000
Weighted Average Remaining Contractual Life	3 years 9 months	3 years 6 months 7 days
Aggregate Intrinsic Value		$ 27,900
Warrant Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price	$ 0.08	$ 0.04
Warrants Exercisable	3,699,320	2,300,000
Weighted Average Remaining Contractual Life	2 months 4 days	4 years 9 months
Aggregate Intrinsic Value		$ 100,970
Warrant Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price	$ 0.2299	$ 0.06
Warrants Exercisable	8,250,000	7,398,639
Weighted Average Remaining Contractual Life	2 years 2 months 15 days	2 months 4 days
Aggregate Intrinsic Value		$ 176,827
Warrant Four [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price	$ 0.16	$ 0.08
Warrants Exercisable	3,125,000	3,699,320
Weighted Average Remaining Contractual Life	2 years 11 months 12 days	2 months 4 days
Aggregate Intrinsic Value		$ 14,427
Warrant Five [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price	$ 0.25	$ 0.08
Warrants Exercisable	8,000,000	3,699,320
Weighted Average Remaining Contractual Life	3 years 2 months 23 days	1 year 2 months 4 days
Aggregate Intrinsic Value		$ 14,427
Warrant Six [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price	$ 0.1160	$ 0.2299
Warrants Exercisable	500,000	8,250,000
Weighted Average Remaining Contractual Life	2 years 6 months 7 days	3 years 2 months 15 days
Aggregate Intrinsic Value
Warrant Seven [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price	$ 0.12	$ 0.16
Warrants Exercisable	12,500,000	3,125,000
Weighted Average Remaining Contractual Life	4 years 18 days	4 years 11 months 12 days
Aggregate Intrinsic Value
Warrant Eight [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price	$ 0.14	$ 0.25
Warrants Exercisable	4,285,714	8,000,000
Weighted Average Remaining Contractual Life	4 years 18 days	4 years 2 months 23 days
Aggregate Intrinsic Value
Warrant Nine [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price		$ 0.1160
Warrants Exercisable		500,000
Weighted Average Remaining Contractual Life		3 years 6 months 7 days
Aggregate Intrinsic Value

SCHEDULE OF OPTIONS OUTSTANDING

SCHEDULE OF OPTIONS OUTSTANDING (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Equity [Abstract]
Exercise Price	$ 0.115	$ 0.115
Options Outstanding
Options Exercisable	26,520,000	26,802,500
Weighted Average Remaining Contractual Life	18 years 6 months 7 days	19 years 1 month 9 days

STOCKHOLDERS_ DEFICIT (Details

STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($)																																																						12 Months Ended
	Nov. 17, 2022	Nov. 14, 2022	Nov. 01, 2022	Oct. 31, 2022	Oct. 26, 2022	Oct. 18, 2022	Oct. 11, 2022	Sep. 26, 2022	Sep. 08, 2022	Aug. 18, 2022	Jul. 19, 2022	Jun. 30, 2022	Jun. 21, 2022	Jun. 14, 2022	Jun. 06, 2022	May 17, 2022	Apr. 29, 2022	Apr. 14, 2022	Feb. 16, 2022	Feb. 16, 2022	Feb. 15, 2022	Jan. 31, 2022	Jan. 21, 2022	Dec. 21, 2021	Dec. 06, 2021	Nov. 22, 2021	Nov. 10, 2021	Oct. 28, 2021	Oct. 25, 2021	Oct. 12, 2021	Oct. 04, 2021	Sep. 20, 2021	Sep. 14, 2021	Sep. 08, 2021	Sep. 03, 2021	Aug. 30, 2021	Aug. 23, 2021	Aug. 16, 2021	Jul. 29, 2021	Jul. 06, 2021	Jun. 23, 2021	Jun. 20, 2021	Jun. 07, 2021	May 04, 2021	Apr. 30, 2021	Apr. 26, 2021	Apr. 23, 2021	Mar. 05, 2021	Mar. 02, 2021	Jan. 25, 2021	Feb. 19, 2020	Mar. 09, 2019	Feb. 16, 2009	Dec. 31, 2022	Dec. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 24, 2021	Dec. 17, 2013
Class of Stock [Line Items]
Number of shares issued																					7,398,639				1,479,728																			1,479,728
Issuance of common stock in connection with warrant exercise																					7,398,639				1,479,728																			1,479,728					1,479,728
Number of shares issued for services, value																					$ 443,918				$ 88,784																			$ 88,784					$ 88,784
Options to purchase shares																																																								2,500,000
Preferred stock, shares authorized																																																					Unlimited	Unlimited		Unlimited
Preferred stock, no par value																																																					$ 0	$ 0		$ 0
Debt Instrument, Increase, Accrued Interest																																																						$ 54,755			$ 40,138
Equity Option [Member]
Class of Stock [Line Items]
Share price																																																		$ 0.134
Options to purchase shares																																																		2,500,000
Fair value of options																																																		$ 310,165
Common stock warrants and options, description																																																		Options vest 33.3% on the year one anniversary of the grant date, 33.3% will vest on the second anniversary, and 33.3% will vest on the third year anniversary as long as the employee remains with the Company at the end of each successive year for three years. Options will be exercisable on January 25, 2021, and for a period of 7 years expiring on January 25, 2028
Share based compensation, expense																																																							$ 98,625
Stock Option One [Member]
Class of Stock [Line Items]
Share price																																																			$ 0.115
Options to purchase shares																																																			6,000,000
Fair value of options																																																			$ 626,047
Share based compensation, expense																																																						104,270
Share based compensation arrangement by share based payment award, description																																																			Black-Scholes option-pricing model on the date of grant and 2,000,000 options are fully vested on the date granted and 1,000,000 options vest at the end of each successive year for four years. Options will be exercisable on February 19, 2021, and for a period of 10 years expiring on February 19, 2030
Stock Option Two [Member]
Class of Stock [Line Items]
Share price																																																			$ 0.115
Options to purchase shares																																																			1,340,000
Fair value of options																																																			$ 133,063
Share based compensation, expense																																																						$ 31,803
Share based compensation arrangement by share based payment award, description																																																			Black-Scholes option-pricing model on the date of grant and 268,000 options are fully vested on the date granted and the remaining option vest equally over the remaining 4 years at the end of each successive year. Options will be exercisable on February 19, 2021, and for a period of 6 years expiring on February 19, 2027
Warrant [Member]
Class of Stock [Line Items]
Number of shares issued																					7,398,639				1,479,728																			1,479,728				786,280	1,479,728
Issuance of common stock in connection with warrant exercise																					7,398,639				1,479,728																			1,479,728					1,479,728
Warrant exercise price per share																																																						$ 0.001		0.001
Number of shares issued for services, value																					$ 443,918																							$ 88,784					$ 88,784
Issuance of common stock in connection with cashless exercise																																																2,000,000
Warrant One [Member]
Class of Stock [Line Items]
Number of shares issued																					3,699,320
Issuance of common stock in connection with warrant exercise																					3,699,320
Warrant exercise price per share																																																						0.04		0.056
Number of shares issued for services, value																					$ 295,946
Warrant Two [Member]
Class of Stock [Line Items]
Warrant exercise price per share																																																						0.08		0.04
Warrant Three [Member]
Class of Stock [Line Items]
Warrant exercise price per share																																																						0.2299		0.06
Warrant Four [Member]
Class of Stock [Line Items]
Warrant exercise price per share																																																						$ 0.16		$ 0.08
Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued																					3,699,320																												1,479,728
Share price																												$ 0.0785
Issuance of common stock in connection with warrant exercise																					3,699,320
Number of shares issued for services, value																					$ 295,946
Options to purchase shares																												750,000
Debt Conversion, Converted Instrument, Shares Issued	5,935,350	5,974,335	9,236,212	6,510,348	5,487,951	4,782,778	2,907,240	3,605,259	3,396,898	4,325,913	4,364,987	3,401,877	3,393,979	2,902,922	3,549,793	3,628,325	4,272,417	2,358,380	3,924,443	3,924,443		4,569,059	3,935,417	5,874,062	5,175,822	3,561,885	3,528,221		3,043,955	4,205,118	2,957,622	4,138,369	2,936,668	4,311,269		2,284,808	3,454,203	2,277,273	3,101,546	2,343,919	2,422,195	1,664,823	2,431,506		2,058,686	2,063,391	836,574
Debt Conversion, Converted Instrument, Amount	$ 150,000	$ 150,000	$ 250,000	$ 150,000	$ 150,000	$ 150,000	$ 100,000	$ 150,000	$ 150,000	$ 200,000	$ 200,000	$ 150,000	$ 150,000	$ 100,000	$ 200,000	$ 200,000	$ 250,000	$ 150,000	$ 250,000	$ 250,000		$ 250,000	$ 250,000	$ 250,000	$ 250,000	$ 200,000	$ 200,000		$ 200,000	$ 250,000	$ 200,000	$ 250,000	$ 200,000	$ 250,000		$ 150,000	$ 200,000	$ 150,000	$ 200,000	$ 200,000	$ 200,000	$ 100,000	$ 200,000		$ 250,000	$ 250,000	$ 100,000
Debt Instrument, Increase, Accrued Interest	$ 164	$ 1,151	$ 301	$ 28,384	$ 370	$ 658	$ 1,753	$ 2,863	$ 4,219	$ 7,644	$ 6,027	$ 3,425	$ 3,068	$ 60,822	$ 5,178	$ 5,726	$ 5,918	$ 1,644	$ 1,164	$ 1,164		$ 42,877	$ 2,260	$ 35,479	$ 1,027	$ 1,603	$ 5,342		$ 1,205	$ 5,671	$ 2,301	$ 4,095	$ 2,630	$ 6,521		$ 3,082	$ 11,397	$ 6,904	$ 11,836	$ 7,671	$ 10,247	$ 60,822	$ 25,644		3,630	$ 3,178	$ 1,644
Fair value of shares issued																																													$ 338,654
Common Class A [Member]
Class of Stock [Line Items]
Share price																																			$ 0.0807
Number of shares issued for services, value																																			$ 242,100
Number of shares issued for services																																			3,000,000
Common stock, shares authorized																																																					Unlimited	Unlimited		Unlimited
Common stock, no par value																																																					$ 0	$ 0		$ 0
Common Class A [Member] | Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued for services																																																								3,000,000
Common Class B [Member]
Class of Stock [Line Items]
Common stock, shares authorized																																																					Unlimited	Unlimited		Unlimited
Common stock, no par value																																																					$ 0	$ 0		$ 0
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, no par value																																																						$ 0		$ 0			$ 0
Purchase Agreement [Member] | Warrant [Member]
Class of Stock [Line Items]
Issuance of common stock in connection with warrant exercise																																																	1,479,728
Warrant exercise price per share																																																	$ 0.06			$ 0.06
Warrant expiration date																																																	Mar. 08, 2021			Mar. 08, 2021
Purchase Agreement [Member] | Warrant One [Member]
Class of Stock [Line Items]
Issuance of common stock in connection with warrant exercise																																																	1,479,728
Warrant exercise price per share																																																	$ 0.06			$ 0.06
Warrant expiration date																																																	May 08, 2021			Mar. 08, 2022
Purchase Agreement [Member] | Warrant Two [Member]
Class of Stock [Line Items]
Issuance of common stock in connection with warrant exercise																																																	1,479,728
Warrant exercise price per share																																																	$ 0.06			$ 0.08
Warrant expiration date																																																	Jul. 08, 2021			Mar. 08, 2022						Dec. 08, 2021
Purchase Agreement [Member] | Warrant Three [Member]
Class of Stock [Line Items]
Issuance of common stock in connection with warrant exercise																																																	1,479,728
Warrant exercise price per share																																																	$ 0.06			$ 0.08
Warrant expiration date																																																	Sep. 08, 2021			Mar. 08, 2023
Purchase Agreement [Member] | Warrant Four [Member]
Class of Stock [Line Items]
Issuance of common stock in connection with warrant exercise																																																	1,479,727
Warrant exercise price per share																																																	$ 0.06
Warrant expiration date																																																	Nov. 08, 2021
Purchase Agreement [Member] | Investor [Member]
Class of Stock [Line Items]
Number of shares issued																																																				14,797,278
Share price																																																				$ 0.06758
Proceeds from issuance of common stock																																																				$ 1,000,000
Purchase Agreement [Member] | Investor [Member] | 6 Cent Warrants [Member]
Class of Stock [Line Items]
Issuance of common stock in connection with warrant exercise																																																				14,797,278
Warrant exercise price per share																																																				$ 0.06
Purchase Agreement [Member] | Investor [Member] | 8 Cent Warrant [Member]
Class of Stock [Line Items]
Issuance of common stock in connection with warrant exercise																																																				7,398,639
Warrant exercise price per share																																																				$ 0.08
Purchase Agreement [Member] | Investor [Member] | Common Class A [Member]
Class of Stock [Line Items]
Number of shares issued																																																				14,797,278

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative)

3 Months Ended

6 Months Ended

12 Months Ended

Feb. 15, 2022 USD ($) shares

Dec. 06, 2021 USD ($) shares

Sep. 03, 2021 USD ($)

Jul. 01, 2021 USD ($) m²

May 04, 2021 USD ($) shares

Mar. 02, 2021 USD ($)

Sep. 05, 2019 USD ($) ft²

Aug. 15, 2019 USD ($)

Jul. 03, 2019 USD ($) $ / shares shares

May 09, 2019 USD ($) m²

Apr. 26, 2019 USD ($)

Mar. 01, 2019 USD ($) shares

Jan. 01, 2019

Jan. 23, 2017 USD ($)

Jan. 14, 2016 USD ($) $ / shares shares

Jan. 20, 2015 USD ($) $ / shares shares

Oct. 28, 2011 USD ($) shares

Nov. 10, 2010 USD ($)

Dec. 26, 2006 USD ($)

Aug. 08, 2006 USD ($)

May 08, 2006 USD ($)

Dec. 31, 2022 USD ($) $ / shares

Dec. 31, 2021 USD ($)

Mar. 30, 2023 USD ($)

Dec. 31, 2022 USD ($) $ / shares

Dec. 31, 2021 USD ($)

Dec. 31, 2017 USD ($)

Dec. 31, 2016 USD ($)

Dec. 31, 2015 USD ($) shares

Jul. 02, 2021 USD ($) m²

Dec. 31, 2020 USD ($)

Aug. 08, 2019 $ / shares shares

Sep. 13, 2017 USD ($)

May 28, 2015 $ / shares shares

Loss Contingencies [Line Items]

Annual salary

$ 779,742

$ 734,427

Accrued salary balance

$ 3,077,393

$ 2,991,191

3,077,393

2,991,191

Number of shares issued | shares

7,398,639

1,479,728

1,479,728

Payment for debt

60,000

50,000

Stock issued during period, value

$ 443,918

$ 88,784

$ 88,784

$ 88,784

Accrued Interest payable

31,657

31,657

$ 5,479

Area of land | ft²

5,000

Annual rent, year one

$ 42,000

42,242

42,242

$ 39,200

Annual rent, year two

$ 44,800

$ 8,644

$ 8,644

$ 42,000

Socialist Republic of Vietnam [Member]

Loss Contingencies [Line Items]

Area of land | m²

4,560.57

6,000

Rent increase percentage

5%

Annual rent, year one

$ 8,645

Annual rent, year two

$ 45,150

Common Class A [Member]

Loss Contingencies [Line Items]

Stock issued during period, value

$ 242,100

Maximum [Member]

Loss Contingencies [Line Items]

Warrant exercise price per share | $ / shares

$ 0.08

$ 0.08

Mr. Jonathan R. Rice [Member]

Loss Contingencies [Line Items]

Payroll payment

$ 3,728

3,195

$ 3,728

3,195

Board of Directors Chairman [Member]

Loss Contingencies [Line Items]

Accrued salary balance

1,243

1,065

1,243

1,065

Employment Agreement [Member] | Chief Executive Officer [Member]

Loss Contingencies [Line Items]

Agreement term description

The term of the agreement is a five year period

Annual salary

$ 210,000

422,561

$ 315,764

$ 297,889

$ 281,027

Annual salary rate, increase

6%

Agreement term

5 years

5 years

5 years

Employment Agreement [Member] | Employee [Member]

Loss Contingencies [Line Items]

Employee bonus rate

20%

Employment Agreement [Member] | Mr. Jonathan R. Rice [Member]

Loss Contingencies [Line Items]

Annual salary

$ 20,000

$ 20,000

Annual cash compensation

$ 140,000

$ 120,000

Educational expenses

$ 11,000

Warrants term

3 years

3 years

5 years

3 years

Warrant to purchase common stock shares | shares

6,000,000

2,000,000

121,448

6,000,000

3,000,000

Warrant exercise price per share | $ / shares

$ 0.001

$ 0.001

$ 0.2299

$ 0.001

Warrants maturity date

May 20, 2026

May 28, 2022

One-time bonus

$ 20,000

Employment Agreement [Member] | Mr. Kenneth Le [Member]

Loss Contingencies [Line Items]

Annual cash compensation

$ 60,000

Warrants term

3 years

Warrant to purchase common stock shares | shares

2,000,000

Warrant exercise price per share | $ / shares

$ 0.2299

License Agreement [Member]

Loss Contingencies [Line Items]

Agreement term

20 years

License fee

$ 10,000

License maintenance fee

10,000

Annual research fee

$ 13,700

Number of shares issued | shares

2,200,000

Royalty percentage

2%

Termination agreement description

The Company can terminate the agreement upon a 90 day written notice subject to payment of a termination fee of $5,000 if the termination takes place within 2 years after its effectiveness, $10,000 if the termination takes place within 4 years after its effectiveness and $20,000 if the Agreement is terminated after 4 years

License termination fee

$ 5,000

Payment for debt

60,000

License Agreement [Member] | Common Class A [Member]

Loss Contingencies [Line Items]

Number of shares issued | shares

4,025,652

Payment for debt

$ 265,244

Stock issued during period, value

$ 281,659

License Agreement [Member] | Maximum [Member]

Loss Contingencies [Line Items]

Patent maintenance and prosecution related to license cost

$ 10,000

Intellectual Property Transfer Agreement [Member] | Kim Thompson [Member]

Loss Contingencies [Line Items]

Payment for debt

$ 120,000

Debt instrument maturity date

Dec. 26, 2007

Outstanding balance

65,292

65,292

65,292

65,292

Accrued Interest payable

1,962

1,962

Operating Lease Agreements [Member]

Loss Contingencies [Line Items]

Payments for rent

2,508

Operating lease term, description

the Company signed a new two-year lease for this 5,000 square foot property in Lansing, MI that commenced on October 1, 2019 and ends on September 30, 2021, for its research and development headquarters

Operating Lease Agreements [Member] | Forecast [Member]

Loss Contingencies [Line Items]

Payments for rent

$ 44,800

Operating Lease Agreements [Member] | Office and Manufacturing Space [Member] | July 1, 2021 and ending on September 30, 2022 [Member]

Loss Contingencies [Line Items]

Payments for rent

42,000

Operating Lease Agreements [Member] | Socialist Republic of Vietnam [Member]

Loss Contingencies [Line Items]

Payments for rent

$ 8,645

$ 45,150

Operating Lease

5 years

5 years

Area of land | m²

6,000

4,560.57

Rent increase percentage

5%

Operating Lease Agreements [Member] | President [Member]

Loss Contingencies [Line Items]

Payments for rent

$ 960

$ 0

$ 3,683

$ 0

$ 3,683

Operating Lease

8 years

SCHEDULE OF ACCOUNTS PAYABLE AN

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES RELATED PARTY (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Related Party Transactions [Abstract]
Accounts payable - related party	$ 356,191	$ 347,156
Accrued expenses - related party	3,082,363	2,995,452
Accrued interest - related party	2,276,454	1,901,952
Total accounts payable and accrued expenses - related party	$ 5,715,008	$ 5,244,560

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)																																		3 Months Ended		9 Months Ended	12 Months Ended
	Jan. 26, 2022	Dec. 01, 2020	Nov. 17, 2020	Nov. 04, 2020	Oct. 19, 2020	Sep. 10, 2020	Aug. 12, 2020	Jul. 16, 2020	Jun. 03, 2020	Apr. 08, 2020	Mar. 09, 2020	Feb. 19, 2020	Jan. 24, 2020	Dec. 18, 2019	Nov. 20, 2019	Mar. 01, 2019	Feb. 15, 2019	Feb. 01, 2019	Jan. 17, 2019	Jan. 04, 2019	Jan. 04, 2019	Dec. 21, 2018	Oct. 12, 2018	Oct. 01, 2018	Jul. 05, 2018	Jun. 29, 2018	Jun. 21, 2018	Apr. 26, 2018	Mar. 31, 2018	Jan. 08, 2018	Dec. 02, 2017	Jan. 23, 2017	Jun. 06, 2016	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2022	Dec. 31, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Debt instrument, interest rate, stated percentage																																	3%
Repayment of debt	$ 40,000
Loans payable amount	$ 40,000																																	$ 1,617,000	$ 1,657,000		$ 1,617,000	$ 1,657,000
Paid-in-kind interest																																				$ 61,968	80,849	82,851
Interest payable																																		54,755		$ 40,138	54,755
Interest payable																																		107,882			107,882
Accounts payable related party																																		356,191	347,156		356,191	347,156
Accrued expenses related party																																		3,082,363	2,995,452		3,082,363	2,995,452
Accrued interest related party																																		2,276,454	1,901,952		2,276,454	1,901,952
Accrued interest related party																																		5,714,008	5,244,560		5,714,008	5,244,560
Operating Lease Agreements [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Payments for rent																																					2,508
Stockholder [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Loan received		$ 70,000	$ 35,000	$ 30,000	$ 30,000	$ 100,000	$ 100,000	$ 100,000	$ 150,000	$ 100,000	$ 100,000	$ 100,000	$ 100,000	$ 100,000	$ 100,000	$ 20,000	$ 20,000	$ 30,000	$ 30,000	$ 3,000	$ 17,000	$ 20,000	$ 11,000	$ 26,000	$ 20,000	$ 15,000	$ 15,000	$ 20,000	$ 15,000	$ 100,000	$ 30,000		$ 50,000
Debt instrument, interest rate, stated percentage																																	3%
President [Member] | Operating Lease Agreements [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Lessee, Operating Lease, Term of Contract																																8 years
Payments for rent																																$ 960		$ 0	$ 3,683		$ 0	$ 3,683

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - shares	Feb. 16, 2023	Feb. 15, 2022	Dec. 06, 2021	May 04, 2021
Subsequent Event [Line Items]
Number of shares issued		7,398,639	1,479,728	1,479,728
Subsequent Event [Member]
Subsequent Event [Line Items]
Number of shares issued	2,434,211
Issuance of cashless warrant exercise	2,500,000